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Amyotrophic Lateral Sclerosis (ALS) is the third most common adult onset 
neurodegenerative disorder worldwide. It is generally characterized by progressive 
paralysis starting at the limbs ultimately leading to death caused by respiratory failure. 
There is no cure and current treatments fail to slow the progression of the disease. As 
such, new treatment options are desperately needed. Epigenetic targets are an 
attractive possibility because they are reversible.  
Chapter 1 presents an introduction to ALS and epigenetics. Epigenetics refers to 
heritable changes in gene expression unrelated to changes in DNA sequence. Three 
main epigenetic mechanisms include the methylation of DNA, micro-RNAs and the post-
translational modification of histone proteins. Histone modifications occur in many 
amino acid residues and include phosphorylation, acetylation, methylation as well as 
other chemical moieties. Recent evidence points to a possible role for epigenetic 
mechanisms in the etiology of ALS. Here we review recent advances linking ALS and 
 v 
epigenetics, with a strong focus on histone modifications. Both local and global changes 
in histone modification profiles are associated with ALS drawing attention to potential 
targets for future diagnostic and treatment approaches. 
Chapter 2 presents a survey of the histone PTM landscape in the FUS and TDP-
43 proteinopathy overexpression yeast models. A prominent feature of ALS is the 
accumulation of protein inclusions in the cytoplasm of degenerating neurons; however, 
the particular protein comprising these inclusions varies. The RNA-binding proteins 
TDP-43 and FUS are most notable in ALS. Here, we comprehensively delineate histone 
PTM profiles in ALS yeast proteinopathy models. Remarkably, we find distinct changes 
in histone modification profiles for each. We detect the most striking changes in the 
context of FUS aggregation: changes in several histone marks support a global 
decrease in gene transcription.  
Chapter 3 presents how treating FUS yeast with trichostatin A suppresses growth 
suppression. The FUS protein aggregates and forms inclusions within affected neurons. 
However, the precise mechanisms connecting protein aggregation to neurotoxicity 
remain under intense investigation. Recent evidence points to the contribution from 
epigenetics to ALS. Here, we describe the first report of amelioration of disease 
phenotypes by controlling histone acetylation on specific modification sites. We show 
that inhibiting histone deacetylases (HDACs), via treatment with TSA, suppresses the 
toxicity associated with FUS overexpression in yeast by preserving the levels of 
H3K56ac and H3K14ac without affecting FUS expression or its aggregation. Our data 
raises the novel hypothesis that the toxic effect of protein aggregation in 
neurodegeneration is related to its association with altered histone marks.  
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Chapter 4 presents our model of how FUS is dysregulating PTMs and 
contributing to toxicity in the yeast overexpression model. We interrogated the binding 
partners of FUS by co-immunoprecipitation assays followed by identification by mass 
spectrometry. We identified that Nop1, a histone methyltransferase involved in rRNA 
biogenesis, is a binding partner of FUS. We then measured the levels and localization 
of the histone modifying enzymes Ipl1, Gcn5 and Rtt109 which are responsible for the 
deposition of H3S10ph, H3K14ac and H3K56ac, respectively. We did observe a change 
in the levels of these enzymes, but found that Ipl1 and Rtt109 are significantly excluded 
for the nucleus, while the former colocalizes with FUS. We also found that FUS-RNA 
binding is not necessary for histone PTM dysregulation. We propose that exclusion of 
Ipl1 from the nucleus is driving the dysregulation of histone PTMs and that reduced 
levels of H3K56ac and FUS-Nop1 binding are causing reduced total RNA levels, likely 
representing decreased rRNA which contributing to FUS overexpression toxicity. 
Chapter 5 presents the role H3S10ph in the pathology of C9orf72 ALS and 
identifies Ipl1/Aurora B Kinase as a possible therapeutic target. The most common 
genetic cause of ALS is an accumulation of hexanucleotide repeat expansions (HREs) 
in the C9orf72 gene. HREs in C9orf72 lead to the production of dipeptide repeat 
proteins (DPRs), including proline-arginine (PR). DPRs and PR have linked to a number 
of cellular deficits, but how DPRs influence the epigenome is still poorly understood. 
Here, we show that overexpression of PR50 in yeast is associated with significantly 
increased phosphorylation levels H3S10ph. Remarkably, induced pluripotent stem cells 
and fibroblasts derived from C9orf72 ALS patients display significant increases in the 
levels of H3S10ph. We also find Aurora B Kinase, the human homologue of Ipl1, to be 
 vii 
enriched in nucleus in C9orf72. Furthermore, we show that knockdown of Ipl1, Aurora B 
kinase yeast homolog, abates H3S10ph to control levels and rescues growth 
suppression elicited by PR50. Overall, we show that the DPR PR is connected to 
increased levels of H3S10ph, and identify Aurora B Kinase as a possible therapeutic 
target in the treatment of ALS. 
Our results highlight a great need for the inclusion of epigenetic mechanisms in 
the study of neurodegeneration. We hope our work will pave the way for discovery of 
more effective therapies to treat patients suffering from ALS and other 
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Chapter 1: Introduction1,a 
1.1 Amyotrophic Lateral Sclerosis 
 Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease 
characterized by the selective loss of both upper and lower motor neurons.2 As motor 
neurons in the spinal cord, brain, and brainstem weaken, skeletal muscular atrophy 
spreads through the patient.3 Depending on the type of motor neurons affected, ALS 
can present itself clinically as either limb onset-manifesting as muscle weakness- or 
bulbar onset manifesting as speech impediments.2 Prognosis is poor and quality of life 
is significantly reduced as most patients succumb to the disease within three years of 
diagnosis.4 There is no cure for ALS and the only two FDA approved drugs, RilutekÒ 
(riluzole) and RadicavaÒ (edaravone), fail to stop progression of the disease.5-7  
ALS is classified into two categories: familial and sporadic. Familial ALS 
represents about 10% of all cases, where the disease can be attributed to a particular 
gene mutation running in families.8 Sporadic cases, on the other hand, represent the 
remaining 90% for which there is no family history of the disease. Numerous genes 
have been associated to ALS.9 Some of these include superoxide dismutase 1 (SOD1), 
chromosome 9 open reading frame 72 (C9orf72), Fused in Sarcoma (FUS), and TAR 
DNA binding protein 43 (TDP-43).10 Both familial and sporadic cases share similar 
pathology; the overwhelming majority of cases present neuronal TDP-43 protein 
aggregates.11 Interestingly, not only neuronal cells are affected by these mutations. Glial 
cells harboring SOD1 mutations have been shown to drive motor neuron degeneration  
a https://doi.org/10.1016/j.trsl.2018.10.002 
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in experimental models.12-15 More specifically, microglia bearing a SOD1 mutation 
caused motor neuron degeneration in otherwise healthy mice,16 and human derived 
motor neurons co-cultured with these microglia showed signs of motor degeneration as 
well.17 Nevertheless, the true origin of ALS remains obscure. Therefore, there is an 
urgent need to understand the pathogenesis of ALS in order to develop new treatment 
options. Aberrant epigenetic mechanisms linked to ALS are beginning to be discovered. 
These are attractive therapeutic targets as they are pharmaceutically accessible and 
largely reversible.18  
1.2 Epigenetics 
Epigenetics refers to heritable alterations in gene expression without modification 
to the genome.19 Three main epigenetic mechanisms include DNA methylation, micro 
RNAs (miRNA), and histone post-translational modifications (PTMs).  
1.2.1 DNA methylation 
DNA methylation takes place on the 5’ carbon on cytosine bases and is involved 
in transcription regulation.20 DNA methylation at enhancers is key in determining cell 
line fate.21 Hypermethylation at gene promoters is generally found to silence gene 
expression, while methylation in the coding region can increase transcription. DNA 
methylation is a crucial rate-controlling step that occurs in genomic regulatory regions 
during transcription, making it detectable and possibly even reversible for treatment 
purposes.22  
1.2.2 micro RNA 
miRNAs are key regulators of gene expression.23 miRNAs are non-coding short 
pieces of RNA, containing approximately 22 nucleotides, that generally bind to the 3’-
 3 
untranslated region (3’-UTR) of mRNA, causing degradation of the mRNA and 
translational silencing.  
1.2.2 Histone post-translational modifications 
Histones are proteins which package and organize cellular DNA.24 146 bases of 
DNA coil around two H2A/H2B dimers and one H3/H4 tetramer. The histone N-terminal 
tails are heavily modified with a multitude of chemical moieties, including mono-, di- and 
tri-methylation, acetylation, phosphorylation, SUMOylation and ubiquitination occurring 
in a variety of residues.25 Histone post-translational modifications (PTMs) play an 
important role in gene regulation by controlling the accessibility of DNA to the 
transcriptional machinery. Initially, histone PTMs were thought to only impact gene 
transcription by controlling how tightly DNA wraps around the histones. For example, 
histone acetylation on lysine residues lowers the positive charge on histones and the 
strength of interaction with the negatively charged DNA backbone favoring gene 
transcription. Conversely, hypoacetylation is associated with transcriptional silencing.26-
29 More recently, it has been established that these modifications actually comprise a 
“histone code” that other proteins can ‘write,’ ‘erase’ and ‘read.’30, 31 Histone PTMs can 
also affect one another through ‘cross talk.’32 For example, the phosphorylation of 
Serine 10 on Histone H3 (H3S10ph) promotes acetylation on Lysine 16 on Histone H4 
(H4K16ac) and also inhibits tri-methylation on Lysine 9 on Histone H3 (H3K9me3).33, 34 
1.3 Epigenetic contributions to ALS 
While a thorough understanding of the underlying mechanisms resulting in ALS 
have yet to be reached, recent evidence shows that alterations in the epigenetic 
landscape might contribute to disease pathology. Here, we review recent evidence 
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showing a link between ALS and epigenetics. While we incorporate exciting findings 
featuring DNA methylation and miRNA mechanisms, we mostly focus on recent 
advances linking histone PTMs to ALS. 
1.3.1 DNA methylation in ALS 
 DNA methylation on cytosine bases is one the most studied epigenetic factors in 
neurodegenerative diseases and ALS.18 In post-mortem spinal tissue from sporadic ALS 
patients, there are global alterations in DNA methylation and hydroxymethylation.35 Not 
surprisingly, many of the genes that were hypo- or hypermethylated showed 
corresponding changes in decreasing or increasing gene expression. Interestingly, 
these genes were largely involved with the immune and inflammatory responses. Other 
reports link Dnmt3a, a de novo DNA methyltransferase, to ALS phenotypes.21, 36-38 Mice 
lacking Dnmt3a are hypoactive, underperformed on tests of neuromuscular function and 
motor coordination and had decreased numbers of motor neurons akin to SOD1 mouse 
models of ALS.36 Interestingly, Dnmt3a is required for the development of motor 
neurons in vitro.21 Moreover, apoptosis observed in NSC34 cells treated with 
camptothecin and in wild-type mice with unilateral nerve avulsion was driven by 
increased activity of Dnmt3a, Dnmt1 – a maintenance DNA mehtyltranserfase – and 
increased levels of 5-methyltransferase.37 Remarkably, Dnmt inhibition with RG108, a 
DNA methyltransferase inhibitor, blocked apoptosis in both cultured neurons and mice. 
In agreement, levels of Dnmt1, Dnmt3a and 5-methylcytosine are upregulated in the 
brain and spinal cords of ALS patients.37 Furthermore, Dnmt3a was found in the 
mitochondria of the CNS and skeletal muscle of adult wild-type mice, but was 
significantly reduced in the mitochondria of ALS SOD1 mice.38 Counter intuitively, there 
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was also an increase in mitochondrial DNA methylation in the SOD1 mice, including at 
the 16S ribosomal RNA gene, which encodes for the mitochondrial 16 S rRNA subunit. 
The SOD1 mice also displayed increased mitophagy- the degradation of the 
mitochondria by way of autophagy- which contributed to neuronal degeneration. 
Recently, genome-wide association studies discovered differentially methylated 
genes involved in pathways important to ALS and frontotemporal dementia(FTD)-ALS.39 
In the FTD-ALS subgroup, pathway analysis revealed three gene sets displaying 
enriched DNA methylation; among these is the Meissner Brain HCP with H3K4me3 and 
H3K27me3 gene set. This gene set contains genes with high-CpG-density promoters 
(HCP) bearing the bivalent histone H3 trimethylation mark at K4 and K27 (H3K4me3 
and H3K27me3),40 suggesting that both DNA methylation and histone PTMs are 
important in the progression of FTD-ALS. Interestingly, H3K4me3 and H3K27me3 are 
associated with neurological function.41 For an in-depth examination of the links 
between DNA methylation and ALS, we direct the reader to a thorough review by Martin 
& Wong.42 
1.3.2 miRNA and ALS 
miRNAs are an epigenetic mechanism that reduce gene expression by binding 
Argonaute 2 and forming the RNA-induced silencing complex (RISC).43, 44 The complex 
then binds the 3’-UTR of a specific mRNA, and degrades it if there is an extensive 
match between the mRNA and miRNA or, if there is a less extensive match, just binds 
the mRNA repressing expression of the bound transcript.45-47 miRNAs are associated 
with neurodegenerative diseases such as Alzheimer’s Disease,48 Parkinson’s 
Disease,49 and Huntington’s Disease.50 Several lines of evidence link ALS to miRNA 
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dysregulation.18, 51 For instance, there is a global decrease in miRNA levels in the spinal 
cords of ALS patients.52 The levels of miRNAs were compared to healthy controls and 
90 miRNAs were found to be dysregulated. These miRNAs had mRNA targets involved 
in cell death, immune response and brain development that may possibly contribute to 
ALS etiology. Some of these included upregulation of miR-155 and miR-142. These 
miRNA target ubiquilin 2 (UBQLN2), the RNA binding protein Fox-1 (RBFOX1) and 
reelin (RELN), a protein secreted by certain neurons to guide neuronal migration.53 All 
of these genes have been associated with neurodegeneration.52 Interestingly, genes 
involved with immune response were also found to be dysregulated in sALS patients 
with aberrant DNA methylation patterns.35 This suggests a role for epigenetics 
contributing to cellular demise caused by inflammation in ALS. Furthermore, TDP-43 
overexpression in AinV15 mouse embryonic stem cells inhibited the endogenous 
activity of miRNAs regulating the genes EIF2C4/AGO4.52 These genes are members of 
the RNA-induced silencing complex- the ribonucleoprotein complex that is responsible 
for translational silencing by cleaving miRNA and complementary mRNAs- and have 
been found to be dysregulated in ALS.54, 55 Moreover, a large number of miRNAs were 
differentially expressed in the spinal cord motor neurons of sporadic ALS patients.56 
Functional analysis revealed the some of the upregulated miRNAs could bind to the 3’-
UTR of low molecular weight neurofilament (NFL),56 an important cytoskeleton protein 
involved in mitochondrial transport in motor neurons,57 leading to a decrease in NFL 
mRNA levels. Interestingly, protein levels of NFL are found to lowered in ALS.58-60 
Additionally, FUS disrupts the circuitry between miR-409 and miR-495 in motor neurons 
derived from embryonic mouse cells with a FUS knock-in mutation.61 miR-409 and miR-
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495 regulate the expression of Gria2, which encodes for a subunit of a-amino-3-
hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor. The upregulation of 
these miRNAs led to a decrease in Gria2 mRNA. The authors validated that miR-409 
and miR-495 bind the 3’-UTR of Gria2. Furthermore, FUS stabilizes the interactions 
between the miRNA and their target, leading to decreased Gria2 expression.61 Gria2 
alteration has been previously implicated in motor neuron degeneration via alterations in 
Ca2+ homeostasis leading to excitotoxicity.62-64  
In light of all these alterations, miRNA profiling has been proposed as a potential 
biomarker panel for neurodegeneration and ALS (Table 1).51 For example, microarray 
analysis of leukocytes from sporadic ALS patients compared with healthy controls 
revealed a eight miRNAs that were dysregulated.65 Of these miRNA, only miR-338-3p 
was upregulated, and interestingly it has been previously found to be dysregulated in 
the brains of ALS patients.66 A study of skeletal tissue from SOD1 G93A mice revealed 
that miR-206 was upregulated, and confirmed to also be upregulated in the plasma of 
ALS patients.67 Similarly, comparison of circulating miRNAs in plasma form sporadic 
ALS patients and healthy controls revealed nine dysregulated miRNAs, three of which 
were upregulated.68 Two of these miRNAs, has-miR-46469-5p and has-miR4299, were 
confirmed to be respectively up- and down-regulated in a larger ALS patient cohort. 
Interestingly, both of these miRNAs target EPHA4, a gene that is has been associated 
with ALS in animal models.69 EPHA4 contributes to brain development and neuronal 
migration, much like RELN discussed above.52 These results suggest epigenetic 
mechanisms may be contributing to ALS pathology through alterations in development. 
Furthermore, a number of miRNAs have been found to be dysregulated in the 
 8 
leukocytes of ALS patients.70 Specifically, AAKT, which encodes for miR-338, is up-
regulated, while DNM2, which encodes for miR-638, is down-regulated. Both of these 
miRNAs have been found to be involved in other neurodegenerative diseases, such as 
FTD and hereditary spastic paraplegia.71, 72 Overall, miRNAs appear to play an 
important role in the pathology of ALS and show promise as robust diagnostic 
biomarkers.  
1.3.3 Histone modifications and chromatin remodeling enzymes in ALS 
 Compared to other diseases, the study of epigenetic mechanisms involved in 
ALS is just in its beginning stages and relatively few studies examining the association 
between epigenetics and the disease have been carried out. While most investigations 
have focused in DNA methylation, recent evidence has linked aberrant changes in 
histone PTMs levels to neurodegenerative disease and ALS.8, 18, 73  
Remarkably, many enzymes responsible for installing or removing histone 
modifications have also been associated with ALS (Table 2). For instance, histone 
acetyltransferases (HATs) and histone deacetylases (HDACs) are responsible for the 
addition and removal of acetyl groups on histones, respectively. There are two classes 
of HDACs that are Zn2+ dependent including HDACs 1-11. A third class, Sirtuins (SIRT) 
1-7, are NAD+ dependent.74 HDACs are drug targets for the treatment of many 
diseases, including cancer, inflammatory disease and pulmonary disease.75-77 
Correspondingly, there are a variety of kinases responsible for phosphorylating 
histones, including Aurora B kinase and AMP kinase.78 Lastly, many histone 
methyltransferases are responsible for the deposition and removal of methyl groups on 
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lysine and arginine residues on histones.79 These enzymes can be specific to mono-, di- 
and tri-methylation, as well as symmetric and asymmetric methylation.80  
1.3.3.1 Histone acetylation, HATs and HDACs 
Histone acetylation has been repeatedly associated with ALS. In a FUS 
overexpression model in HeLa cells, FUS binds to and inhibits CBP/p300 HAT at a 
specific gene promoter and causes hypoacetylation near the CCND1 gene.81 This 
causes reduced expression of CCND1, which encodes for cyclin D1, a protein required 
for progression through the cell cycle.82 HeLa cell models have been repeatedly used in 
ALS research.83-85 Evidencing another link between histone acetylation and ALS, ELP3 
– a protein with HAT activity- was linked to motor neuron degeneration in ALS in a 
microsatellite-based genetic association study.86 In zebra fish embryos, ELP3 knock 
down with anti-sense RNA leads to motor neuron degeneration in a dose dependent 
manner.86 ELP3 acetylates Lysine 14 on Histone H3 (H3K14) and Lysine 8 on Histone 
H4 (H4K8).87 Interestingly, mutagenesis screening in Drosophila revealed that ELP3 is 
critical for neuronal communication and survival.86 These results support a role for 
histone hypoacetylation in ALS pathology. In fact, ELP3 directly regulates heat shock 
protein 70 (HSP70) expression by acetylation of histones H3 and H4 in yeast;88 hence, 
ELP3 defects could result in motor neuron degeneration through a decrease in the 
transcription of HSP70.82 
Recently, we characterized global histone acetylation levels in yeast ALS 
proteinopathy models.73 Many cellular pathways are conserved from yeast to humans.89, 
90 Furthermore, yeast recapitulate the cellular toxicity and cytoplasmic foci of TDP-43 
and FUS seen in human pathology.91, 92 In fact, yeast models have enabled 
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identification of common ALS genetic risk factors.93 Yeast overexpressing human FUS 
showed significantly decreased levels of acetylation on Lysine 14 and Lysine 56 on 
Histone H3 (H3K14 and H3K56).73 These histone PTM are conserved in humans. 
H3K14ac and H3K56ac are both involved in the DNA damage checkpoint activation.94-96 
Furthermore, H3K14ac is also found at the promoter of actively transcribed genes.97 
Interestingly, yeast overexpressing FUS had overall decreased RNA levels, suggesting 
that histone hypoacetylation leads to reduced transcription.73 Surprisingly, an analogous 
TDP-43 yeast proteinopathy model did not display the same decreases in histone 
acetylation, but instead revealed hyperacetylation on Lysines 12 and 16 on Histone 4 
(H4K12 and H4K16). H4K12ac is a modification localized on gene promoters and is 
associated with gene activation.98 H4K16ac is a particularly interesting modification 
because it is associated with both gene expression and repression.99, 100 Remarkably, 
each proteinopathy displayed its own distinct histone modification landscape. 
Puzzlingly, while both of these models share protein aggregation and cytotoxicity 
features, FUS and TDP-43 overexpression resulted in histone hypo- and 
hyperacetylation, respectively.  This suggests that each proteinopathy and 
corresponding histone PTM profile may be leading to ALS in unique ways. 
In addition to changes on histone acetylation, HDACs have been thoroughly 
implicated in ALS.101 For instance, deletion of Set3- a member of a histone deacetylase 
complex, homolog to the human protein ASH1- was found to suppress the toxicity of 
TDP-43 inclusions in a yeast model.102 Moreover, post-mortem analysis of brains and 
spinal cord tissue derived from ALS patients showed a decrease in HDAC 11 mRNA 
and an increase of HDAC 2 mRNA.103 Furthermore, HDAC 1 has been found to 
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mislocalize to the cytoplasm in a FUS knock-in mouse model.104 Curiously, post-
translational modification on the histone modifiers themselves appears to be important. 
Phosphorylation of serine residues in HDAC1 controls its subcellular localization, and 
HDAC1 accumulation in the nucleus was neuroprotective in a mouse model.105 Further 
evidence for HDAC perturbations in ALS comes from SOD1 mouse models. SIRT1 
levels are decreased in neurons and increased in muscles of mice expressing mutant 
SOD1, while SIRT2 mRNA levels decrease in motor neurons in the same model.106 In 
NSC34 and HEK293 cells as well as mice expressing wild type and mutant SOD1G93A, 
HDAC6 knock-down induced SOD1 aggregation resulting in increased motor neuron 
loss.107 In the same mice model, HDAC6 levels drop as ALS symptoms appear and 
then plummet as the disease progresses.108 Interestingly, in this mouse model HDAC6 
overexpression prolongs life span and delays motor neuron decay by inducing fusion of 
autophagosomes to lysosomes and promoting autophagy.108  
HDAC cofactors also appear to play a role in disease.109 For example, loss of 
NAD+, a SIRT cofactor, contributes to neurodegeneration.110 Furthermore, the loss of 
intracellular nicotinamide phosphoribosyltranferase- the rate limiting enzyme in NAD+ 
synthesis- leads to motor neuron degeneration in mice where the gene was knocked 
out.111 Increased activity of PARP1 has been observed to deplete NAD+ pools, and 
contributes neurotoxicity.112 Interestingly, silencing of Parp1 is neuroprotective in a 
mouse model of cerebellar ataxia,112 and it is a possible therapeutic target for 
neurodegeneration.  
HDAC inhibition has arisen as a promising therapeutic in various ALS models. 
Treatment with trichostatin A, an HDAC inhibitor, ameliorated motor neuron 
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degeneration in a SOD1 mouse model.113 In motor neurons derived from ALS patients, 
pharmacological inhibition and genetic silencing of HDAC6 reverses axonal transport 
defects caused by mutant FUS.114 Furthermore, HDAC inhibition with 4-PB increased 
motor function and neuroprotection in transgenic ALS mice.115 Interestingly, treatment 
with sodium phenylbutryate, a general HDAC inhibitor, extended survival in SOD1G93A 
ALS mouse model,116 and its effect is increased when combined with an antioxidant or 
Riluzole.117, 118 Phenylbutyrate has shown to be safe and increase histone acetylation 
levels in ALS patients.119 Perplexingly, loss of HDAC function and is related to disease 
in some models,113-116 while HDAC inhibition is neuroprotective in others.104, 106-108 
Future studies will potentially reconcile these seemingly opposite landscapes and 
elucidate their contribution to ALS pathways. 
1.3.3.2 Histone methylation and methyltransferases 
 Lysine and arginine methylation have varying effects on gene expression. 
Generally, mono-methylation is associated with transcription activation, while tri-
methylation is associated with transcription repression.120 Recent evidence has linked 
tri-methylation of lysine residues on H3 and H4 with loss-of-function toxicity in ALS 
patients with dipeptide repeat expansions (DRE) in C9orf72.121 There is an increase in 
H3K9me3, H3K27me3 and H4K20me3 levels around the DREs sequence in brain 
tissue from ALS patients compared to healthy controls. These histone PTMs are 
strongly associated with gene silencing.120 Decreased levels of C9orf72 mRNA in 
patients support a loss-of-function toxicity model.121 Interestingly, treating fibroblasts 
derived from patients bearing C9orf72 mutations with a histone demethylating agent 
reduced tri-methylation levels near DREs and restored C9orf72 mRNA levels.121 
 13 
 In yeast models of ALS, we observed distinct histone methylation profiles for 
TDP-43 and FUS proteinopathies.73 Specifically, FUS overexpression is associated with 
decreased levels of asymmetric di-methylation on Arginine 3 on Histone H4 
(H4R3me2asym), while TDP-43 overexpression is associated with decreased levels of 
tri-methylation on Lysine 36 on Histone H3 (H3K36me3). H34Rme2asym is associated 
with increased gene expression,122 whereas H3K36me3 is linked to transcriptional 
repression by serving as a docking site for HDACs and promoting deacetylation.123, 124 
As for acetylation, these results highlight that different proteinopathies can have unique 
effects on epigenetic mechanisms. H4Rme2 is linked to H3K14ac,125 which also 
decreased in this FUS model, underscoring cross talk between these two modifications.  
 Protein arginine N-methyltranserfase 1(PRMT1) is a methyltransferase that has 
been positively implicated in ALS. PRMT1 is responsible H4R3me2asym, which 
promotes histone acetylation and gene transcription.126 In a FUSR521C mouse model of 
ALS, overexpression of PRMT1 was found to rescue neurite growth after oxidative 
stress.127 The same study showed that PRMT1 activity is inhibited by interaction with 
FUS as a stable complex of FUS/PRMT1/Nd1-L mRNA is formed. Nd1-L is an actin 
stabilizing protein and is under-expressed in this model. Furthermore, in agreement with 
our FUS yeast model results, loss of PRMT1 function -due to FUS mislocalization- led 
to the reduction of di-methylation of Arginine 3 on Histone H4 (H4R3me2) causing a 
drop in the acetylation of Histone H3 on Lysine 9 and 14, ultimately leading to 
transcriptional silencing.128 
1.3.3.3 Histone phosphorylation and ubiquitination 
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 Phosphorylation on serine, threonine and tyrosine histone residues plays an 
important role in gene expression, transition through the cell cycle and DNA damage 
repair.78 Histone phosphorylation and many enzymes responsible for it have been 
implicated in ALS and other neurodegenerative diseases.129 For example, loss of FUS 
through RNAi leads to decreased cell proliferation and an increase in H3 
phosphorylation in NSC-34 and HEK-293T cells.130 This coincides with altered 
expression of genes involved in cell cycle regulation, cytoskeletal organization, oxidative 
stress and energy homeostasis, and may point to a loss-of-function mechanism for FUS 
mutants related to ALS.  
In a FUS overexpression model in yeast, we discovered a reduction in 
phosphorylation levels on Threonine 129 on Histone H2B (H2BT129ph).73 In yeast, 
reduced H2BT129ph is associated with decreased gene expression.131 In the same 
model, we identified a profound decrease in the levels of phosphorylation on Serine 10 
on Histone H3 (H3S10ph). H3S10ph is associated with active gene expression.78 
Furthermore, H3S10ph promotes acetylation of Histone H3 on Lysine 14 (H3K14ac) in 
yeast,132 suggesting histone cross-talk may play an important role in disease processes. 
Interestingly, Ilp1, the yeast homologue of human Aurora B kinase, can phosphorylate 
both H3S10 and H2BT129. These results suggest Aurora B kinase might be involved in 
ALS pathology. 
Increased R-Loops (DNA-RNA triple helixes) and DNA double strand breaks 
were observed in vitro and in the spinal tissue of ALS patients with mutations in 
C9orf72.133 This damage was associated with dipeptide repeats in C9orf72 causing an 
accumulation of P62 and impaired H2A ubiquitination at lysine 119 (H2AK119ub1). P62 
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is an autophagy protein related to ALS, and its accumulation inhibits RNF168, the 
enzyme responsible for ubiquitination on H2A.134 Reduced ubiquitylation impaired ATM 
signaling, an important pathway involved in DNA damage repair,135 and perturbed DNA 
double strand break repair.133 Figure 1 presents all histone modifications linked to ALS 
to date. 
One issue that arises whenever discussing histone modification is causality.136 
Are histone modifications a consequence of neurodegenerative proteinopathies or do 
changes in modifications lead to disease? Further research into how ALS-associated 
proteins interact with histone ‘writers’, ‘erasers’ and ‘readers’, and perhaps even the 
histone PTMs themselves is necessary to definitively answer this question. This may 
still be an emerging field with a number of questions yet to be answered, but as 
discussed above for HDACs inhibitors, drugs targeting histone modifiers are effective 
treatments in ALS models.113-119 Thus, causality might ultimately be inconsequential, as 
pharmaceutical intervention targeting epigenetic features of ALS would alleviate disease 
outcomes. A number of histone modifications are associated with ALS, and each 
enzyme responsible for adding, removing or reading these modifications is a potential 
drugable target. Aside from HATs and HDACs, further research into chemical 
modulation of histone kinases, phosphorylases, methyltransferases and demethylases 
is needed. For example, inhibitors of protein phosphatase 1 and 2, responsible for 
removal of H3S10ph, 137, 138 as well as inhibitors of JMJD6, a Jumonji-domain-
containing protein reported to demethylate H4R3me2139, may be useful therapeutic 
targets for ALS. 
1.3.3.4 Chromatin remodeling enzymes 
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 Eukaryotic DNA is packed into chromatin. DNA wraps around histones to form 
nucleosomes, the basic units of chromatin. Chromatin structure affects gene expression 
by controlling the accessibility to DNA.140 Transcriptionally active chromatin is termed 
euchromatin and while transcriptionally silent chromatin is referred to as 
heterochromatin.25, 141 Chromatin plays a key role in nearly all eukaryotic DNA-
templated processes such as mitosis, DNA repair, and transcription.  Some histone 
PTMs directly contribute to chromatin structure. For instance, H4K16ac inhibits the 
formation of heterochromatin,142 while H3K9me3 binds Heterochromatin Protein 1 
promoting chromatin compaction.34 Additionally, enzymes that target histone PTMs can 
also play a role in chromatin compaction. For example, the HDAC SIRT1, which 
deacetylates H4K16, also has the ability to dephosphorylate the active site of the 
methyltransferase suppressor of variegation 3-9 homologue 1 (SUV39H1), increasing 
its activity and consequently increasing H3K27me3 levels and promoting chromatin 
compaction.143 Aside from enzymes that directly affect histone PTMs, there a number of 
ATP-dependent chromatin remodeling enzymes that move, eject or otherwise 
restructure histones to control chromatin structure.144, 145Some of these have been 
associated to ALS and neurodegenerative disease. For example, in a TDP-43 
overexpression Drosophila model, the chromatin-helicase-DNA binding protein Chd1 
was inhibited by TDP-43, which in turn inhibited the stress response needed for 
neuronal survival.146 Chd1 alters gene accessibility by modifying chromatin structure.147 
This loss of Chd1 function led to decreased expression of protective genes, such as the 
proteins involved in the REST and Hsp70 pathway. Correspondingly, up-regulation of 
Chd1 was found to be neuroprotective. The human orthologue of Chd1, CHD2, 
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physically interacted with TDP-43 and was significantly reduced in the temporal cortex 
of patients with ALS.146 Therefore, at least some of toxicity associated with TDP-43 
seems to be caused by the reduced expression of protective genes caused by 
chromatin rearrangement.  
 POLR2A, a subunit of the carboxyl-terminal domain of RNA Polymerase II, reads 
modifications specifying the recruitment of factors that regulate transcription, mRNA 
processing and chromatin remodeling.148 Arginine 1810 of POLR2A is symmetrically di-
methylated by protein arginine methyltransferase 5 (PRMT5) and this modification 
recruits the Tudor domain of survival of motor neuron (SMN). SMN interacts with 
senataxin, which is sometimes mutated in ALS.149 Perturbations in this pathway lead to 
the formation of R-loops, genomic instability and pre-mature transcription termination 
causing neurodegeneration.148  
Furthermore, RNA Polymerase II, as well as TDP-43 and FUS, colocalize with 
gH2AX (a histone H2A isoform phosphorylated on serine 139).150 gH2AX is a sign of 
DNA double strand breaks.151 gH2AX co-localization with TDP-43 and FUS suggests 
these proteins may have a role in double strand break repair. DNA double strand breaks 
may be harder to resolve when FUS or TDP-43 mislocalize from the nucleus, promoting 
neurodegeneration and suggesting a loss-of-function toxicity model for these two ALS-
associated proteins. A summary of the histone and chromatin modifying enzymes 
implicated in ALS is presented in Table 2. 
 Mounting evidence highlights the role of epigenetic mechanisms in ALS 
pathology. DNA methylation, miRNAs and histone PTMs have distinct contributions to 
neurotoxicity. The evidence reviewed here reveals distinct DNA methylation patterns 
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and dysregulation of miRNAs are associated with ALS. Although understudied, 
perturbations in the levels of histones modifications lead to alterations of gene 
expression and can contribute to the neurodegeneration. Remarkably, these alterations 
seem to be distinctly connected to different proteinopathies. Chromatin remodeling 
enzymes, which do not specifically impact histone modifications, also contribute to ALS 
pathology by reducing expression of survival genes and impairing DNA break repair. 
Though exact knowledge of how the different epigenetic mechanisms, in particular 
histone PTMs, affect ALS development and progression is still lacking, we are 
beginning to characterize them and realizing their potential importance in understanding 
ALS. Although much work remains to elucidate causal relationships and mechanisms 
linking histone PTMs and neurodegeneration, these findings highlight the critical need 
for the inclusion of epigenetics in neurodegenerative disease research. Remarkably, 
some of these altered epigenetic profiles can be detected in blood, and may become 
useful biomarkers for diagnosis and assessment of disease or treatment progress. We 
expect discoveries to come in the next decade will take us beyond establishing the links 
between ALS and epigenetics and move towards elucidating the precise epigenetic 
mechanisms associated with disease processes and specific symptoms. Pinpointing 
how epigenetic changes relate to disease can potentially lead to novel diagnostic and 




Table 1. List of miRNAs that may act as possible biomarkers for Amyotrophic 
Lateral Sclerosis. Adpadted from Bennett et al., Transl Res, 2019. 
 
miRNA Dysregulation Tissue Reference 
 





miR-206 Upregulated Plasma of sporadic 
ALS patients 
47 
has-miR-46469-5p Upregulated Plasma of sporadic 
ALS patients 
48 




miR-338 Upregulated Leukocytes of ALS 
patients 
50 






Table 2. List of epigenetic enzymes involved in Amyotrophic Lateral Sclerosis. 
*Sirtuin cofactor involved in ALS pathology. Adpadted from Bennett et al., Transl Res, 
2019. 




CBP/p300 Reduced activity when 
interacting with FUS 
80 
ELP3 Required for neuronal 
communication and 




HDAC1 Mislocalizes to cytoplasm 
in FUS ALS model 
103 
Accumulation in nucleus 
is neuroprotective 
104 
HDAC2 Levels decrease in spinal 
tissue of ALS patients 
102 




neuroprotective in mouse 
model 
107 
HDAC11 Levels increase in the 
spinal tissue of ALS 
patients 
102 
SIRT1 Levels increase in the 
muscles of a mutated 
SOD1 mouse model 
105 
SIRT2 Levels decrease in motor 
neurons of a mutated 
SOD1 mouse model 
105 






PRMT1 Overexpression rescues 
neurite growth in FUS 
model 
126 
Reduced methylation of 
H4R3, ultimately leading 
to gene silencing  
127 








Inhibited by TDP-43, 
inhibited stress response 
required for neuronal 
survival 
145 






Figure 1. Histone post-translational modifications linked to different 
proteinopathies and genes in Amyotropic Lateral Sclerosis. Arrows denote an 
increase or a decrease for a given modification in the context of ALS. Adpadted from 





Chapter 2: ALS proteinopathies are connected to distinct histone 
post-translational modification landscapes.73,a 
2.1 Rationale for studying ALS proteinopathies in Yeast 
Is there a role for epigenetics in neurodegenerative disease? Recent evidence 
has linked ALS to epigenetic mechanisms (reviewed in18, 152, 153). Thus far, DNA 
methylation has been the dominant subject of research on epigenetics of 
neurodegenerative disease. Nevertheless, there is evidence for the importance of 
histone modification in this context. For instance, overexpression of wild type FUS 
induces hypoacetylation of histone H3 on a specific gene promoter.154 Moreover, the 
levels of HDAC1, HDAC2 and Sirtuins (a family of class III histone deacetylases) have 
been found to be impaired in postmortem ALS tissues.155, 156 Indeed, FUS itself has 
been shown to interact with HDAC1 to recruit the latter to sites of DNA damage.157 More 
recently, redistribution of wild-type or mutant FUS to the cytoplasm has been associated 
with a loss-of-function in the arginine methyltransferase PRMT1 resulting in alterations 
in histone PTMs.128 Despite all the evidence for an epigenetic component in ALS, a 
comprehensive study of the histone modifications involved in these diseases has not 
been carried out to date.  
 Yeast is a useful model for studying neurodegenerative diseases because it 
preserves many neuronal cellular pathways and upon TDP-43 or FUS overexpression it 
recapitulates proteinopathies and cytoplasmic foci seen in ALS.89, 90, 158-160 In contrast to 
other ALS model systems, yeast are inexpensive, expeditious and easy to work with. In 




the human protein ASH1—has been found to suppress the toxicity of TDP-43 inclusions 
in a yeast model.162 Furthermore, yeast models for other ALS-related proteinopathies 
have also identified chromatin proteins as modifiers of protein aggregation cytotoxicity.89 
Here, we exploit FUS and TDP-43 yeast proteinopathy models to identify perturbations 
in histone PTMs patterns by way of western blotting using modification-specific 
antibodies. To the best of our knowledge, this is the first comprehensive 
characterization of histone PTMs in any ALS model. Remarkably, we find distinct 
changes in histone modification profiles for each proteinopathy model. Our results 
highlight FUS aggregation to be associated with the most pronounced changes in 
several histone marks including phosphorylation of histone H2B, phosphorylation and 
acetylation on histone H3, as well as histone H4 arginine dimethylation. Furthermore, 
we observe a global decrease in gene transcription in the context of FUS proteinopathy. 
We also identify more moderate histone PTMs disturbances in cells overexpressing 
TDP-43 and α-synuclein. Small increases in the levels of histone acetylation on lysine 
12 and 16 on histone H4 as well as a small decrease in the level of trimethylation of 
lysine 36 on histone H3 are apparent in the context of TDP-43 overexpression. Overall, 
our results highlight a great need for the inclusion of epigenetic mechanisms in the 
study of neurodegenerative disease and the search for more effective treatments for 
these disorders.  
2.2 TDP-43 and FUS proteinopathies elicit distinct perturbations in the histone 
PTMs landscape 
 Using modification-specific antibodies, we have delineated the global epigenetic 
make up of TDP- 43 and FUS proteinopathies. To do this, we exploited well-established 
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yeast models for ALS.159, 160, 163, 164 Previous investigations have found these show 
cytoplasmic foci in 90% of cells in TDP-43 and FUS models.165 Yeast were transformed 
with either a control vector or vectors expressing TDP-43 or FUS. Spotting assays on 
inducing selective media corroborated growth of control cells and cytotoxicity of TDP-43 
and FUS.  In our experiments, FUS overexpression was the most toxic, followed by 
TDP-43. (Figure 2a,b). Galactose-induced protein expression was verified by western 
blotting for both constructs (Figure 2c,d). In liquid culture, cytotoxic phenotypes are 
much less severe (Figure 2e). After galactose induction, we harvested and lysed both 
control yeast and yeast overexpressing TDP-43 or FUS. The timeframe of cell harvest 
for histone modification analysis precedes the point of toxicity in liquid culture (Figure 
2e). Cell lysates were subjected to SDS-PAGE to separate histone proteins from all 
other proteins. We then probed for individual histone modifications using commercially 
available modification-specific antibodies. We selected immunoblotting methods 
because of their high sensitivity of detection for low- abundance proteins and 
modifications.166 In this work, we focused primarily on histones H3 and H4, as these 
histones are most pervasively modified.167 Furthermore, we included histone 
modifications involved in both transcriptional activation and repression. Altogether, we 
incorporated 24 histone modifications in our experiments. Individual histone 
modifications were quantitated by blot image analysis, normalized to the loading control 
and compared to the control sample to obtain fold change measurements. Remarkably, 
we identified distinct histone PTM panoramas for each proteinopathy (Figure 3). P-
values were used to assess the statistical significance of observed changes. Due to 
large variations observed in some of the histone modifications, the p-values provide a 
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better representation of the observed PTM changes than the averages and were thus 
used to construct the heat map in Figure 3. Overall, we found TDP-43 overexpression 
to be associated with increases in several histone PTMs, while FUS overexpression is 
associated with highly significant decreases in histone modification levels. As a positive 
control illustrating the potential range of changes on histone modification levels, we 
treated wild type cells with the DNA-damage agent bleomycin, which induces both 
single-stranded and double-stranded DNA damage.168 We explored the levels of 
phosphorylation on histone H2A on serine 129, which is homologous to phosphorylation 
on S139 in humans and a notable histone modification occurring in response to a DNA 
double strand break.169, 170 After bleomycin treatment, we observe a ~2.5-fold increase 
in the phosphorylation of serine 129 in histone H2A (Figure 4). In general, it is important 
to note that statistical significance does not correlate with magnitude of the change in 
histone PTMs levels. For instance, in the context of TDP-43 overexpression, changes 
on histone H3K36me3 levels are highly reproducible and thus significant statistically 
(Figure 3), but very modest in magnitude. Altogether, our results suggest the observed 
epigenetic changes are specific to each individual proteinopathy and not associated 
with general protein aggregation toxicity pathways. Furthermore, we found that ALS 
proteinopathies are connected to widespread changes in histone modifications 
throughout the genome that are detectable without the need for enrichment of any 
particular genomic regions. 
2.3 Histone PTM dysregulation in TPD-43 and FUS models 
2.31. Histone H3 methylation 
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  To our surprise, many of the histone H3 methylation sites we probed display 
similar modification levels in both control cells and proteinopathy models. In particular, 
all degrees of methylation (me1, me2, and me3) on lysine 4 and lysine 79 showed no 
changes (Figures 5 and 6). We did not study methylation on lysine 9 because this 
modification is not present in budding yeast.171 We note no genome-level disturbances 
in the levels of H3K79me3, which along with H3K9me3, H3K27me3 and H4K20me3, 
has been implicated in particular genetic loci in other proteinopathies related to ALS.172 
However, we found an exception in changes on the levels of di- and tri-methylation of 
histone H3 at lysine 36. In yeast, H3K36 is methylated by the methyltransferase Set2, 
which can install up to three methyl groups on the lysine side chain.173 Interestingly, the 
human counterpart of Set2, SETD2, interacts with huntingtin protein pointing to a 
potential role for this modification in neurodegenerative disease.174 H3K36 methylation 
has been implicated in transcriptional elongation, suppressing histone exchange and 
hyperacetylation as well as promoting maintenance of chromatin structure over coding 
regions in order to prevent aberrant transcriptional initiation within coding sequences.175 
While the levels of H3K36me2 do not change in FUS and TDP-43 models (Figure 7a), 
we found the levels of H3K36me3 were modestly decreased when TDP-43 is 
overexpressed (Figure 7b), but remained unchanged in the FUS model.  
2.3.2 Histone H3 acetylation and phosphorylation 
We observed the most sizeable changes in histone H3 PTMs levels in the 
context of FUS overexpression. In particular, we detected a 50% decrease in the levels 
of phosphorylation of H3 on serine 10 (Figure 8a). This change in H3S10ph is 
unmatched in the TDP-43 overexpression models. H3S10ph has been linked to both 
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transcriptional activation and repression. Ipl1, the yeast homolog of the mammalian 
Aurora B Kinase, is responsible for its installation.176 Highlighting its importance, this 
modification is remarkably conserved throughout the eukaryotic kingdom.177 The striking 
alteration in the levels of this modification might point to an important role for Aurora B 
Kinase in ALS etiology. Indeed, Aurora B Kinase has been shown to phosphorylate 
Ataxin-10, a key protein in Spinocerebellar ataxia type 10, another neurodegenerative 
disorder.178 Unfortunately, we are unable to pinpoint if decreases in H3S10ph arise from 
alterations in the levels of Ipl1 as antibodies for this protein are unavailable. To clarify 
whether the observed alterations in histone modifications are related to protein toxicity 
and/or expression levels, we lowered toxic protein expression levels by growing cells on 
a combination of galactose and sucrose. Sucrose gets slowly metabolized to glucose, 
and glucose in turn represses the galactose promoter.179 First, we verified the 
sucrose/galactose setup reduced FUS expression (Figure 9c). Unsurprisingly, 
decreased expression of FUS lessened the toxic phenotypes observed on solid and 
liquid media (Figure 9a-b, respectively). Indeed, we find lowered levels of FUS resulted 
in decreased magnitude of change in the level of phosphorylation of Histone H3 on 
Serine 10 (Figure 9d-e). 
We also observed important hypoacetylation of H3 on lysine 14 in the FUS model 
(Figure 9b). We did not observe parallel acetylation changes in the TDP-43 
overexpression model. Furthermore, we detected no alternations in the acetylation 
levels of histone H3 on lysine 9, lysine 18 or lysine 27 in either of our proteinopathy 
models (Figure 10). Past research linked overexpression of wild type FUS to 
hypoacetylation on both K9/K14 in the cyclin D1 gene promoter in human cells.154 
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However, as this investigation used an antibody that recognized K9/K14 acetylation in 
tandem, it is hard to compare our findings. Generally, hypoacetylation is correlated to a 
tighter association between histones and DNA and the establishment of transcriptionally 
inactive heterochromatin.180-182 However, it is striking that we did not observe a general 
reduction in acetylation for all sites, but rather we determined that FUS proteinopathy is 
associated with loss of acetylation at specific histone H3 sites. H3K14ac is involved in 
DNA damage checkpoint activation and DNA repair,183, 184 and thus lowered levels 
suggest DNA repair is impaired in the FUS model. Furthering this hypothesis, H3K56ac 
– an acetylation site in the core domain of H3- is also significantly lowered in the FUS 
proteinopathy model (Figure 8c). This modification is required to reinstate chromatin 
structure over repaired DNA, and is critical for signaling completion of repair.185 Akin to 
H3K14ac, we did not detect statistically significant changes in the levels of H3K56ac in 
the TDP-43 overexpression models.  
2.3.3 Histone H4 methylation 
In conjunction to the changes on H3 modification outlined above, we also 
identified a decrease on the levels of dimethylation on arginine 3 on histone H4 in the 
FUS model (Figure 11a). This is in agreement with the H3K14 hypo-acetylation we 
observe, as H4R3me2 has been associated with H3 acetylation at both lysine 9 and 
lysine 14.186 In yeast, Hmt1, the yeast homolog of the protein arginine methyltransferase 
1 (PRMT1), catalyzes the formation of H4R3me2.187 PRMT1 has been found to interact 
with and methylate FUS, affecting its cellular localization.188-192 Consistent with our 
findings, expression and mislocalization of wild type or mutant human FUS in cultured 
murine motor neurons has been previously found to lead to nuclear depletion of PRMT1 
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and a consequent reduction in the levels of H4R3me2.128 It is possible that FUS is 
sequestering Hmt1 and localizing to the cytoplasm resulting in hypo-methylation at this 
site. It is also conceivable mislocalized protein sequesters other histone modifiers 
resulting in the various changes on histone modification levels we detect. Moreover, 
H4R3me2 has been associated with transcriptional activation.193 Together with lowered 
acetylation on H3K14 and H3K56, decreased H4R3me2 would suggest a decrease in 
gene transcription. We found no statistically significant changes in the level of 
H4R3me2 in the TDP-43 model. Furthermore, we observed no alterations in any of the 
other histone H4 modifications studied in the FUS overexpression background, 
including symmetric dimethylation on R3 (Figure 12).  
2.3.4 Histone H4 acetylation 
 In contrast to observed changes in the FUS model, we encountered modest 
hyper-acetylation of histone H4 on lysine 12 and lysine 16 in the TDP-43 proteinopathy 
model compared to control (Figure 11b-c).  Histone acetylation has been long 
correlated with transcriptional activation.194 In yeast, the specific removal of H4K16ac 
enables the formation of a heritably silent state,195 and thus increases in this 
modification would suggest enhanced gene transcription in the TDP-43 background. 
Interestingly, increased levels of H4K12ac have been found in Alzheimer’s disease 
mouse models during early development of the disease.196  
2.3.5 Histones H2.A & H2.B 
 We discovered considerable hypo-phosphorylation of histone H2B on threonine 
129 in the FUS proteinopathy model (Figure 13). Loss of phosphorylation at this site is 
associated with decreased gene expression as well as DNA damage.197, 198 While this 
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modification is not conserved in humans, we included it in our analysis as we 
anticipated it could yield important information on the biological pathways linked to ALS 
pathology. We observed a 50% decrease in the level of H2BT129ph in cells 
overexpressing FUS compared to control cells (Figure 13). Changes in this modification 
fit together with changes in H3K14ac and H3K56ac (Figure 8b-c) and stress a role for 
DNA damage and repair in FUS proteinopathy. Furthermore, activation of poly (ADP-
ribose) polymerase 1 (PARP-1) in response to DNA damage has been found to inhibit 
Aurora B Kinase,199 and thus changes in H3S10ph levels in the FUS model would also 
correspond with triggering of the DNA damage signaling. Puzzlingly, we found no 
significant differences in the levels of phosphorylation on histone H2A on serine 129 in 
any of the proteinopathy models (Figure 14). This raises the possibility that the 
combination of modifications observed in the FUS model is not occurring in association 
to DNA damage, but are instead related to other processes. It is plausible that the 
histone modifications we observe arise in association to unidentified defense 
mechanisms triggered by the cytotoxicity of the protein aggregates.  
2.4 Total RNA levels are decreased in the FUS yeast model 
 Collectively, many of the alterations on histone modifications observed in the 
FUS model point to decreased gene transcription. To further validate this hypothesis, 
we chose a straightforward approach in which we extracted and quantitated total RNA 
in each proteinopathy model and compared them to control. As we expected, total RNA 
levels were lower in the FUS overexpression background compared to control (Figure 
15). Together with our histone modification data, we interpret this result to indicate a 
global decrease in gene expression occurs in the FUS model. This finding agrees with 
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previous investigations, which found transcriptional activity to be decreased in neurons 
presenting FUS mislocalization.128 Notably, we observed this effect despite protein 
overexpression. As FUS is a RNA-binding protein, it is possible that it sequesters RNA 
in protein aggregates. However, we did not observe a similar effect in the context of 
TDP-43 overexpression. TDP-43 is also a RNA- binding protein, and thus if the change 
in RNA levels resulted from sequestration then this effect should be present in the TDP-
43 samples as well. While the histone modification changes observed in the TDP-43 
model (increases in histone H4 acetylation as well as H3K36me3) support 
transcriptional activation, it is possible that the increased gene transcription corresponds 
to specific genomic loci and thus it would not be detected by changes in total RNA 
levels. 
2.5 Histone crosstalk in FUS and TPD-43 yeast models 
We present a summary of all observed histone PTMs changes in Figure 16. 
Extraordinarily, we found very little overlap between the histone PTM alterations elicited 
in the two proteinopathy model. Overall, we found the most and most intense 
modification changes to be associated with FUS proteinopathy, followed by TDP-43 
proteinopathies. Unsurprisingly, the number and magnitude of changes appear to 
correlate with cytotoxicity of protein expression. Remarkably, we only observe 
modification increases in the TDP-43. Altogether, our data indicates important 
decreases in histone phosphorylation and acetylation are associated with cytotoxic 
phenotypes.  
Our data also underscores histone crosstalk between modifications and provides 
hints regarding the mechanisms of PTM interaction. For instance, we observed 
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decreases in both H3S10ph and H3K14ac in the FUS proteinopathy background 
(Figure 16). In yeast, H3S10ph has been shown to promote acetylation of H3K14 by 
Gcn5 at specific gene promoters.200 Thus, it is not surprising to observe that these two 
modifications decrease in tandem. In the context of FUS overexpression, we also 
observe decreases in H2BT129ph (Figure 16). Ipl1 –the yeast homolog of Aurora B 
Kinase- has been shown to be able to phosphorylate H2B.201 Therefore, decreases in 
the phosphorylation of these two sites might be pointing at Ipl1 impairment in FUS 
proteinopathy. Lastly, we observed evidence for inter-histone crosstalk, as we identify 
decreases in both H4R3me2 and H3K14ac (Figure 16). H4R3me2 has been previously 
linked to histone H3 acetylation at both lysine 9 and lysine 14.186 Other correlations 
present in our data could arise from yet undiscovered crosstalk processes. 
It is important to note that our data is limited to yeast models of ALS, and thus 
verification in other model systems is still lacking. Furthermore, it is difficult to establish 
causal relationships from our experiments: do changes in histone modifications lead to 
disease processes or do disease processes lead to changes in histone modifications? 
Issues of causality are a struggle for the field of histone modifications at large.202 
Nevertheless, we establish a clear association between strong decreases in histone 
phosphorylation and acetylation with most severe cytotoxic phenotypes. Furthermore, 
we observe changes in histone PTMs as early as five hours into protein overexpression. 
Regardless of causation, histone modification pathways are highly accessible 
pharmacologically and thus they hold great promise for disease treatment. 
Recent work has targeted several histone ‘writers’ and ‘erasers’ to ameliorate 
ALS phenotypes. Notably, HDAC inhibitors have been used with success in mice ALS 
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models.101 In ALS mice models, treatment with an HDAC inhibitor led to neuroprotection 
and improved motor function,203 while treatment with phenylbutyrate (a general HDAC 
inhibitor) significantly extended survival and improved clinical and neuropathological 
phenotypes.116 Our findings highlight further histone modifiers as potential targets for 
pharmaceutical intervention. In addition to reversing decreases in histone acetylation, 
novel chemical intervention strategies aimed at reversing decreases in histone 
phosphorylation and methylation could potentially improve cell survival in the context of 
neurodegenerative disease. Based on our results, inhibitors for Protein Phosphatase 1 
and 2, which remove H3S10ph,177, 204 as well as inhibitors of JMJD6, a Jumonji domain-
containing protein reported to demethylate H4R3me2,205 could become useful 
therapeutic avenues for ALS.  
2.5 Conclusions 
We have carried out the first comprehensive characterization of histone 
posttranslational modifications in any ALS models. Remarkably, we discover that 
distinct changes in histone modification profiles for each proteinopathy model 
evidencing that histone PTM changes are not associated with general protein 
aggregation toxicity pathways. Furthermore, we find widespread changes detectable in 
whole genome samples. Our results highlight FUS aggregation to be associated with 
the most pronounced changes in several histone marks including phosphorylation of 
histone H2B, lysine phosphorylation and acetylation on histone H3, as well as histone 
H4 arginine methylation. We also observe a global decrease in gene transcription in the 
context of FUS proteinopathy. Furthermore, we identify moderate disturbances in 
histone modification patterns in cells overexpressing TDP-43. Our data corroborates 
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previous findings in different model systems, while significantly broadening our 
knowledge of the epigenetic landscape of neurodegenerative disease. The expanded 
set of modifications we present here could uncover novel histone ‘writer’ and ‘eraser’ 
targets for pharmacological intervention. Overall, our results underscore the potential 
importance of epigenetic mechanisms in the occurrence and progression of ALS and 
other neurodegenerative diseases and lead to novel, more effective therapies for these 
ailments.  
2.6 Experimental Methods 
 
Materials. All chemicals were purchased from Sigma Aldrich (St. Louis, MO) unless 
otherwise specified. 
Yeast Strains, Media, and Plasmids. All yeast were W303a (MATa, can1-100, his3-
11,15, leu2-3,112, trp1-1, ura3-1, ade2-1).90 Yeast were grown in synthetic dropout 
media (Clontech Laboratories, Inc., Mountain View, CA). Media was supplemented with 
2% glucose, raffinose, or galactose. Vectors encoding TDP-43, FUS, and α-synuclein 
(pAG303GAL-TDP-43, pAG303GAL-FUS, and pAG303GAL-α-synuclein-GFP, 
respectively) were a gift from A. Gitler. 158, 160, 164 A pAG303GAL-ccdB vector was used 
as a control. pAG303GAL-ccdB was a gift from Susan Lindquist (Addgene plasmid # 
14133). 
Yeast Transformation, Spotting Assays, and Liquid Culture Growth Assay. Yeast 
were transformed according to standard protocols using polyethylene glycol and lithium 
acetate.206 For spotting assays, yeast were grown to saturation overnight in raffinose-
supplemented dropout media at 30ºC. Cultures were diluted 2-fold, serially diluted 2-
fold, and then spotted in duplicate onto synthetic dropout media containing glucose, 
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sucrose galactose or mixtures of sucrose and galactose. Plates were analyzed after 
growth for 2-3 days at 30ºC. For liquid culture growth assays, yeast were grown in 
galactose-supplemented or sucrose/galactose-supplemented media for 48 hours at 
30ºC. Optical density measurements were taken every 24 hours. 
Bleomycin Treatment. Wild-type W303a yeast were grown to saturation overnight at 
30ºC on YPD media (Dot Scientific, Burton, MI, Cat #DSY20092-1000). Yeast were 
standardized to an optical density of 0.3 and grown for 4 hours at 30ºC. Cultures were 
then checked to verify log phase growth and treated with 20 µg/ml bleomycin (EMD 
Millipore Corp., Billerica, MA, Cat # 203401-10MG) for one hour. After treatment, 
cultures were normalized to an optical density of 0.9; 10 mL of cells were then 
harvested and frozen at -80ºC. 
Protein Overexpression. Protein overexpression in yeast was induced in galactose- or 
sucrose/galactose-containing medium for 5 hours (TDP-43 and FUS) or 8 hours (α-
synuclein-GFP) at 30ºC. After induction, cultures were normalized to an optical density 
of 0.9; 10 mL of cells were then harvested and frozen at -80ºC. 
Western Blotting. Frozen yeast cell pellets were thawed and treated with 0.2M NaOH 
for 10 minutes on ice, pelleted again and subsequently resuspended in 100 μL 1×SDS 
sample buffer and boiled for 10 minutes. Cell lysates were separated using SDS-PAGE 
(15%) and then transferred to a PVDF membrane (EMD Millipore, Billerica, MA). 
Membranes were blocked using LI-COR blocking buffer (LI-COR Biosciences, Lincoln, 
NE) for 1 hour at room temperature. Primary antibody incubations were performed at 
4°C overnight. Antibodies used were: rabbit anti-TDP-43 polyclonal (Proteintech, 
Chicago, IL, Cat #10782-2-AP), rabbit anti-FUS polyclonal (Bethyl Laboratories, 
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Montgomery, TX, Cat#A300-302A), and mouse anti-3-phosphoglycerate kinase (PGK) 
monoclonal (Novex, Frederick, MD, Cat#459250). For histone modifications, all 
antibodies were purchased from Abcam (Cambridge, MA) unless otherwise specified: 
H3 (cat #ab24834), H3K4me1 (cat #ab8895), H3K4me2 (cat #ab7766), H3K4me3 (cat 
#ab8580), H3K9ac (cat #ab10812), H3K14ac (Millipore, cat #07-353), H3K18ac (cat 
#ab1191), H3K27ac (cat #ab45173), H3K36me1 (cat #ab9048), H3K36me2 (cat 
#ab9049), H3K36me3 (cat #ab9050), H3K56ac (ActiveMotif, Carlsbad, CA, cat 
#39281), H3K79me1 (Millipore, cat #ABE213), H3K79me2 (cat #ab3594), H3K79me3 
(cat #ab2621), H3S10ph (cat #ab5176), H4 (cat #ab10158), H4K8ac (cat #ab15823), 
H4K12ac (cat #ab46983), H4K16ac (cat #ab109463), H4K20me1 (cat #ab9051), 
H4K20me3 (cat #ab9053), symmetric H4R3me2 (cat #ab5823), H4R3me2 (cat 
#ab194696), H2AS129ph (cat #ab15083), and H2BT129ph (cat #ab188292). Blots were 
processed using goat anti-mouse and anti-rabbit secondary antibodies from LI-COR 
Biosciences (Lincoln, NE) and imaged using an Odyssey Fc Imaging system (LI-COR 
Biosciences, Lincoln, NE). All immunoblotting experiments were repeated a minimum of 
three times with independent cell samples.  
RNA Purification. Yeast were grown and induced in galactose-containing medium for 5 
hours (TDP-43 and FUS). 2 x 107 cells were harvested for each sample and treated with 
100 U Zymolyase-20T (Nacalai USA, San Diego, CA, cat # 07663-91) for 30 minutes at 
30°C. RNA was isolated using the RNeasy Mini Kit from Qiagen (Germantown, MD) 
according to the manufacturer’s instructions. Total RNA levels were measured using a 
NanoDrop Lite spectrophotometer (Thermo Fisher, Waltham, MA). All experiments were 
repeated a minimum of three times with independent cell samples. 
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Data Analysis. Densitometric analysis of Western blots was performed using Image 
Studio (LI-COR). The signals obtained for histone modifications were normalized to their 
respective total histone H3 signals (modification/total H3). These values were then 
compared against the control sample values to obtain fold change values 
(sample/control), which were used for statistical analysis. A similar procedure was used 
to analyze Western blot data from sucrose experiments; the normalized signals were 
compared to the sucrose samples' signals. RNA concentrations were normalized 
against controls to obtain fold change values used for further analysis.  
Statistical Analysis. Statistical analysis of data was performed in R 3.3.1 using the 
built-in stats package (R-Project, Vienna, Austria). Significant differences between 
sample groups (Control vs. TDP-43, Control vs. FUS, and Control vs. α-synuclein) was 
determined using Welch's t-test with p = 0.05 as the cut-off for significance. Error bars 
on the graphs represent the standard error of the mean calculated from values obtained 
in the data analysis step described above. Figure 1 was constructed from these p-
values, which were transformed according to a previously described method using the 
equation, − log 𝑥 ∗ 𝑦, where 𝑥 represents the p-value and 𝑦 represents the sign of the 
test statistic.207 Western blot data from sucrose experiments were analyzed using one-





Figure 2. Yeast expressing TDP-43 and FUS exhibit cytotoxic phenotypes. Spotting assays 
depict cell viability (a) without and (b) with galactose induced expression. Western blots confirm 
the expression of (c) TDP-43 and (c) FUS in these cells. (e) Growth curve illustrating cell 
viability in liquid culture under galactose induction. Error bars indicate the +/- SEM. n=3 for each 






























Figure 3. Histone modifications are altered in the context of yeast overexpressing 
TDP-43 and FUS. p- values for the ratio of histone H2A, H2B, H3 and H4 PTMs 
abundances in yeast strains expressing TDP-43 and FUS relative to control cells are 
shown. The scale is based on p-values derived from statistical analysis of Western 
blotting experiments. p- values were calculated using a two- tailed t-test with Welch's 
modification Green indicates more statistically significant decreased modification levels, 
while red indicates more statistically significant increased modification levels. Adapted 
from Chem, Bennett, et al., ACS Chem. Neurosci, 2018.  
 41 
                    
Figure 4. Levels of histone H2A phosphorylation are Increased in cells treated with 
bleomycin. (a) Representative immunoblots showing the levels of H2AS129ph in yeast cells 
treated with bleomycin. (b) Quantitation histogram compiling multiple biological replicates, 
Graph displays the mean fold change in modification levels for each group based on 
densitometric analysis of Western blots. Error bars indicate the +SEM. n ≥ 3. *p < 0.05. Adapted 







Figure 5. Levels of histone H3 methylation on lysine 4 are not altered in yeast models of 
ALS proteinopathies. Representative immunoblots showing the levels of (a) H3K4me1, (b) 
H3K4me2, and (c) H3K4me3 for TDP-43 and FUS yeast proteinopathy models, respectively. 
Quantitation histograms compiling multiple biological replicates are presented alongside blots. 
All graphs display the mean fold change in modification levels for each group based on 
densitometric analysis of Western blots. Error bars indicate the +SEM. n ≥ 3 for each 





Figure 6. Levels of histone H3 monometylation on lysine 36 And methylation on lysine 79 
are not altered in yeast models of ALS proteinopathies. Representative immunoblots 
showing the levels of (a) H3K36me1, (b) H3K79me1, (c) H3K79me2, and (d) H3K79me3 for 
TDP-43 and FUS yeast proteinopathy models, respectively. Quantitation histograms compiling 
multiple biological replicates are presented alongside blots. All graphs display the mean fold 
change in modification levels for each group based on densitometric analysis of Western blots. 
Error bars indicate the +SEM. n ≥ 3 for each modification. Adapted from Chem, Bennett, et al., 




















Figure 7. The TDP-43 proteinopathy model display decreases in histone H3 tri-
methylation on lysine 36. Representative immunoblots showing the levels of (a) 
H3K36me2, (b) H3K36me3 for TDP-43 and FUS yeast proteinopathy models, 
respectively. Quantitation histograms compiling multiple biological replicates are 
presented alongside blots.  All graphs display the mean fold change in modification 
levels for each group based on densitometric analysis of Western blots. Error bars 
indicate the +SEM. n = 3-7 for each modification. **p < 0.01, ***p < 0.001. Adapted from 




   
Figure 8. FUS overexpression correlates with changes in the phosphorylation of 
serine 10 and acetylation of lysine 14 and lysine 56 on histone H3. Representative 
immunoblots showing the levels of (a) H3S10ph, (b) H3K14ac, and (c) H3K56ac for 
TDP-43 and FUS yeast proteinopathy models, respectively. Quantitation histograms 
compiling multiple biological replicates are presented alongside blots. All graphs display 
the mean fold change in modification levels for each group based on densitometric 
analysis of Western blots. Error bars indicate the +SEM. n = 3-6 for each modification. 





Figure 9. Levels of FUS overexpression correlate with the magnitude of alterations in 
serine 10 phosphorylation in histone H3 (a) Spotting assays depict cell viability in glucose, 
sucrose, galactose and various ratios of galactose and sucrose. (b) Growth curve illustrating cell 
viability in liquid culture in glucose, sucrose, galactose and various ratios of galactose and 
sucrose. Error bars indicate the +/- SEM. n=3 for each growth condition. (c) Western blots 
assess the expression of FUS in each growth condition. (d) Representative immunoblots 
showing the levels of H3S10ph in each growth condition. (e) Quantitation histogram compiling 
multiple biological replicates. Graph displays the mean fold change in H3S10ph levels for each 
growth condition based on densitometric analysis of Western blots. Error bars indicate the 
+SEM. n ≥ 3 for each condition. *p < 0.05. Adapted from Chem, Bennett, et al., ACS Chem. 




Figure 10. Levels of Histone H3 Acetylation on Lysine 9, Lysine 18 and Lysine 27 Are Not 
Altered in Yeast Models of ALS Proteinopathies. Representative immunoblots showing the 
levels of (a) H3K9ac, (b) H3K18ac, and (c) H3K27ac for TDP-43 and FUS yeast proteinopathy 
models, respectively. Quantitation histograms compiling multiple biological replicates are 
presented alongside blots. All graphs display the mean fold change in modification levels for 
each group based on densitometric analysis of Western blots. Error bars indicate the +SEM. n ≥ 







Figure 11. FUS and TDP-43 overexpression correlate with changes in arginine di-
methylation and lysine acetylation on histone H4. Representative immunoblots 
showing the levels of (a) H4R3me2, (b) H4K12ac, and (c) H4K16ac for TDP-43 and 
FUS yeast proteinopathy models, respectively. Quantitation histograms compiling 
multiple biological replicates are presented alongside blots. All graphs display the mean 
fold change in modification levels for each group based on densitometric analysis of 
Western blots. Error bars indicate the +SEM. n = 3-6 for each modification, *p < 0.05. 





Figure 12. Levels of several histone H4 marks are unchanged In yeast models Of ALS 
proteinopathies. Representative immunoblots showing the levels of (a) H4R3me2 (sym), (b) 
H4K8ac, (c) H4K20me1, and (d) H4K20me3 for TDP-43 and FUS yeast proteinopathy models, 
respectively. Quantitation histograms compiling multiple biological replicates are presented 
alongside blots. All graphs display the mean fold change in modification levels for each group 
based on densitometric analysis of Western blots.  Error bars indicate the +SEM. n ≥ 3 for each 





Figure 13. The FUS proteinopathy is associated with changes in histone H2B 
phosphorylation levels. Representative immunoblots showing the levels of 
H2BT129ph for TDP-43 and FUS yeast proteinopathy models. Quantitation histograms 
compiling multiple biological replicates are presented alongside blots. All graphs display 
the mean fold change in modification levels for each group based on densitometric 
analysis of Western blots. Error bars indicate the +SEM. n ≥ 3 for each modification. *p 






Figure 14. Levels of histone H2A phosphorylation are not altered in ALS yeast models. 
Representative immunoblots showing the levels of H2AS129ph for TDP-43 and FUS yeast 
proteinopathy models. Quantitation histograms compiling multiple biological replicates are 
presented alongside blots. All graphs display the mean fold change in modification levels for 
each group based on densitometric analysis of Western blots. Error bars indicate the +SEM. n ≥ 





Figure 15. RNA levels are decreased in a FUS overexpression ALS model Total 
RNA levels in yeast control cells as well as cells overexpressing TDP-43 and FUS. All 
graphs display the mean fold change in total RNA levels for each group. Error bars 
indicate the SEM. n = 3 for each group. *p < 0.05. Adapted from Chem, Bennett, et al., 





Figure 16. Yeast models of neurodegenerative disease proteinopathies are 
connected to distinct histone post-translational modification landscapes. Green 
bars indicate significant decreases, while red bars indicate significant increases relative 
to control samples. Error bars indicate the +SEM. n ≥ 3 for each modification. Adapted 





Chapter 3: Trichostatin A Relieves Growth Suppression and Restores 
Histone Acetylation in a FUS ALS Yeast Model.208,a 
3.1 ALS, histone PTMs and trichostatin A 
HDAC inhibition has arisen as a potential strategy for treating ALS and other 
neurodegenerative diseases. For instance, the HDAC inhibitor Scriptaid can clear SOD1 
aggregates in vitro.115 Moreover, pan-HDAC inhibitors were found to be neuroprotective 
in in vitro and in vivo TDP-43 ALS models.209 Similarly, phenylbutyrate, a general HDAC 
inhibitor, improved clinical and phenotypes in an ALS mouse model.116 Trichostatin A 
(TSA), a pan class I HDAC inhibitor, decreased motor neuron death and axon 
degeneration as well as reduced gliosis in an ALS mouse model.113  
Yeast provides an expedient, cost-efficient model to study certain aspects of 
neurodegeneration. FUS overexpression in yeast recapitulates several features of ALS 
pathology including FUS mislocalization and aggregation.92 Furthermore, in contrast to 
mammalian cellular models, yeast FUS ALS models display overt cellular demise allowing 
for convenient exploration of chemical tools to prevent cell death. Recent evidence has 
tied FUS proteinopathy to the epigenome. FUS overexpression in yeast is associated with 
alterations to the histone PTM landscape.1, 73 In particular, FUS overexpression is 
connected to decreases in the levels of acetylation on Lysines 14 and 56 on Histone H3.73 
Histone PTMs are accessible pharmacological targets, and thus we speculated that 
chemical interventions aimed at modulating relevant epigenetic changes might lead to 





3.2 TSA rescues the growth suppression phenotype observed in FUS yeast 
3.2.1 W303 yeast 
To test if TSA can ameliorate FUS proteinopathy we measured the growth of yeast 
overexpressing FUS or a vector control in various concentrations of the drug. DMSO was 
used as a vehicle control. Serial dilutions were grown on selective media supplemented 
with either glucose or galactose. Glucose suppresses FUS expression, while galactose 
activates it. Both FUS and vector control strains grew well on glucose, regardless of drug 
condition (Figure 17, left panel). Hence, TSA does not appear to impact yeast growth at 
the concentrations used. As previously reported,73, 92 FUS overexpression leads to a 
dramatic decrease in cell growth compared to a vector control (Figure 17, left panel). 
Excitingly, TSA treatment led to amelioration of growth suppression in FUS yeast. Yeast 
overexpressing FUS treated with TSA grow better than their untreated and vehicle control 
counterparts (Figure 17, black arrows). To semi-quantitatively measure the effect of TSA 
treatment on yeast growth in the context of FUS overexpression, we assessed the image 
density of the middle spot from each condition and compared it to the corresponding spot 
in the vector control (Figure 17, right panel). Yeast overexpressing FUS treated with 2.50 
µM TSA grew significantly better than untreated yeast or yeast treated with vehicle control 
DMSO (Figure 17, right panel). FUS yeast treated with either 0.625 µM or 1.25 µM TSA 
grow better than untreated yeast, but did not reach statistical significance (Figure 17, 
right panel). 
3.2.2 DPDR yeast 
To further validate the effect of TSA treatment, we repeated the experiment in a 
different yeast strain. The DPDR1,3 strain is lacking genes for regulation of an ATP-
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binding-cassette that provides multi-drug resistance, rendering them more sensitive to 
drug treatments.210 As expected, FUS overexpression leads to strong growth suppression 
(Figure 18, left panel), which is rescued by treatment with 2.5 µM TSA (Figure 18, right 
panel). Our results establish that interfering with HDAC activity via TSA treatment 
ameliorates the growth suppression phenotype associated with FUS overexpression in 
yeast.  
3.3 TSA does not affect FUS expression or aggregation 
We verified that the reduction of growth suppression was not due to changes in 
the expression or aggregation of FUS. To test the former, we measured total levels of 
FUS expression by Western blotting (Figure 19a). There was no significant difference in 
FUS levels in any of the treatment conditions. Through filter-retention assays, we 
confirmed that TSA treatment did not affect FUS aggregation (Figure 19b) TSA and other 
HDAC inhibitors have been previously shown to trigger expression of Hsp70 which helps 
clear FUS aggregates and reduce proteotoxic stress.211, 212 However, as we see no 
reduction in FUS aggregation, we suspect the toxicity mitigation we observe does not 
involve enhanced proteostasis.  
3.4 TSA restores histone acetylation in FUS yeast 
 
3.4.1 H3K14 and 56ac 
 
 To probe whether detoxification occurred through epigenetic mechanisms, we first 
asked if TSA treatment restored levels of H3K14ac. To assess this, we grew yeast in 
galactose-supplemented liquid media to elicit FUS overexpression and treated the cells 
with no drug, DMSO (vehicle) or 2.50 µM TSA. We selected a concentration of 2.50 µM 
TSA based on our solid media growth results (Figure 17). Western blotting followed by 
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densitometric analysis of H3K14ac specific bands normalized to the H3 total loading 
control yields a fold change for H3K14ac under each condition. Consistent with previous 
results73, untreated and DMSO-treated yeast displayed significantly lower levels of 
H3K14ac compared to the untreated vector control (Figure 20a). Remarkably, FUS yeast 
treated with 2.50 µM TSA showed a significant increase in H3K14ac levels compared to 
untreated FUS yeast and DMSO treated FUS yeast. (Figure 20a). TSA treatment 
restored H3K14ac levels up to control levels (Figure 20a). In the case of H3K56ac, 
acetylation levels were significantly lower in untreated and DMSO-treated FUS yeast 
compared to the vector control. As for H3K14ac, TSA restored H3K56ac up to control 
levels, with TSA treated yeast showing significantly higher acetylation levels than both 
untreated and DMSO treated yeast (Figure 20b). This was surprising because H3K56 is 
deacetylated by Hst3 and Hst4, which are insensitive to TSA.213, 214 Acetylation of H3K56 
is mediated by the lysine acetyltransferase Rtt109 in concert with the chaperones Vsp75 
and Asf1.215, 216  Interestingly, H3K14ac drives Rtt109 to specifically acetylate H3K56ac 
via Asf1 binding.216 Through this crosstalk mechanism, it is possible that H3K14ac 
recovery is promoting a rise in H3K56ac levels.  
3.4.2 TSA does not affect global acetylation level at 2.50 µM  
TSA increases global acetylation levels in yeast, but at concentrations higher than 
those used in this study. 217, 218 To verify that 2.50 µM TSA did not affect acetylation levels 
at other lysine residues not connected to FUS proteinopathy, we measured acetylation 
on H4K16 (Figure 21). TSA treatment did not increase acetylation levels on this residue, 
suggesting that 2.50 µM TSA restores acetylation only on those modification sites that 
are originally impacted by FUS overexpression. To further investigate if 2.50 µM TSA 
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raised acetylation levels outside of the context of FUS proteinopathy, we probed for 
H3K14ac and H3K56ac in vector control yeast, where the levels of these PTMs are not 
decreased. TSA treatment has no significant effect on H3K14ac or H3K56ac levels in 
vector control yeast (Figure 22). 
3.5 TSA does not restore other histone PTM levels in FUS yeast 
As we observed evidence of histone PTM crosstalk, we wondered if other non-
acetyl histone modifications that change in the context of FUS proteinopathy would 
recover in response to TSA treatment. FUS yeast, regardless of treatment conditions, 
retained significantly reduced H3S10ph and H4R3me2asym levels (Figure 23). This 
suggests that the decreases in these PTMs are independent of histone acetylation levels. 
Furthermore, it establishes that the amelioration of growth suppression elicited by TSA is 
not related to changes in the levels of H3S10ph or H3Rme2asym. Akin to histone 
acetylation, TSA treatment did not affect neither H3S10ph nor H4R3me2asym in vector 
control yeast (Figure 24). 
3.6 Conclusions 
Collectively, we show that TSA relieves growth suppression in yeast 
overexpressing FUS. This mitigation of toxicity is accompanied by restoration of H3K14ac 
and H3K56ac levels, but not H3S10ph or H4R3me2asym levels. We did not observe any 
changes in FUS expression or aggregation with TSA treatment. To the best of our 
knowledge, this is the first report of its kind tying specific histone acetylation sites to ALS 
cell demise. Pan-histone acetylation has been shown to increase after HDAC inhibition, 
but specific residues were not implicated.113, 219 Furthermore, our data raises the novel 
hypothesis that the toxic effect of protein aggregation in neurodegeneration is at least in 
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part related to its association with altered histone marks, a notion that is not well 
characterized in ALS. We hypothesize reduction of toxicity occurs through modulation of 
epigenetic pathways. Very recently, pathogenic FUS has been found to interact with 
nucleoporins and impede nucleocytoplasmic transport.220 It is possible that defects in 
nucleocytoplasmic transport result in the cytoplasmic mislocalization of Gcn5, the HAT 
primarily responsible for H3K14 acetylation,221 leading to decreased H3K14ac levels. 
Unfortunately, there are no commercially-available antibodies for yeast Gcn5, which 
preclude straightforward cellular localization studies. H3K56ac might be lowered through 
crosstalk with H3K14ac or by another mechanism. We speculate impaired H3K14ac and 
H3K56ac could then lead to aberrant gene expression and ultimately cell death (Figure 
25). However, further investigation is needed to definitively establish such a mechanism.  
In conclusion, our results highlight that changes in histone PTMs are closely 
associated with the cell demise elicited by FUS proteinopathy. We illustrate the ability to 
counter the detrimental effects of protein aggregation on cell survival by modulating 
specific histone modification changes via chemical treatment. Our results allude to novel 
mechanistic networks involving epigenetics that will enable new treatments for ALS and 
other neurodegenerative diseases. 
3.7 Experimental methods 
Yeast Strains, Media and Plasmids All yeast were W303a (MATa, can1-100,his3-11, 
15,leu2,3,11,12,trp1-1,ura3-1,ade2-1).90 DPDR yeast have the same background with the 
exception of deletion of pdr1 and pdr3. DPDR yeast were a gift from J. Shorter (University 
of Pennsylvania). Yeast were grown in synthetic dropout medium (Clonetech 
Laboratories, Mountain View, CA) supplemented with 2% glucose, raffinose or galactose. 
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The FUS plasmid (pAG303GAL-FUS) was a gift from A. Gitler (Addgene plasmid no. 
29614).92 A control ccdB plasmid, pAG3030GAL-ccdB, was a gift from Susan Lindquist 
(Addgene plasmid no. 14133).90 Yeast were transformed using standard poly(ethylene 
glycol) and lithium acetate protocols.222  
Solid Media Growth Assays Yeast were grown to saturation overnight in raffinose-
supplemented dropout media at 30°C. Overnight cultures were diluted 2-fold, then serially 
diluted 5-fold. A volume of 2 µL for each dilution was pipetted onto synthetic dropout 
medium glucose or galactose containing no treatment, DMSO, 0.625 µM TSA, 1.25 µM 
TSA or 2.50 µM TSA. Plates were analyzed after 3-4 days of growth at RT. Images of the 
plates were imported into ImageJ (Fiji),223 and the density of the middle spot of each plate 
was measured using the oval tool. All experiments were repeated a minimum of three 
times with three independently transformed yeast strains. 
Protein Overexpression Yeast strains were grown to saturation overnight in raffinose-
supplemented dropout media in a shaking incubator at 30 °C and 200 rpm. Overnight 
cultures were then diluted to an OD600 of 0.30 in 50 mL of raffinose-supplemented 
synthetic dropout media and grown for another 4 hours at 30 °C. Cells were then pelleted 
at 850 rcf at 4 °C and washed 3x with sterile distilled water. The pellet was then 
resuspended in 50 mL of galactose-supplemented media with DMSO, 2.5 µM TSA or 
untreated and grown for 5 hours at 30 °C. After induction, cultures were normalized by 
cell count and harvested at 850 rcf at 4 °C for 5 minutes and washed 3X with sterile 
distilled water. Yeast were then resuspended in 500 µL sterile distilled water, evenly split 
into five microcentrifuge tubes and harvested at 850 rcf at 4 °C for 5 minutes. The 
supernatant was removed and the pellets were flash frozen in liquid nitrogen and stored 
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at -80 °C. All experiments were repeated a minimum of three times with three 
independently transformed yeast strains. 
Western Blotting Frozen yeast cell pellets were thawed and treated with 0.2 M NaOH 
for 10 minutes on ice, pelleted again, and subsequently resuspended in 100 µL of 1x SDS 
sample buffer and boiled for 10 minutes. Cell lysates were separated using SDS-PAGE 
(15%) and then transferred to a PVDF membrane (EMD Millipore). Membranes were 
blocked using LI-COR blocking buffer (LI-COR Biosciences, Lincoln, NE) for 1 hour at 
RT. Membranes were incubated with primary antibodies at 4 °C overnight. Primary 
antibodies used were: rabbit anti-FUS polyclonal (Bethyl Laboratories, Montgomery, TX; 
cat. no. A300-302A, 1:1,000 dilution), mouse anti-PGK monoclonal (Novex, Frederick, 
MD; cat. no. 459250, 1:2,000 dilution), mouse anti-H3 total (Abcam, Cambridge, MA; cat. 
no. ab24834, 1:2,000 dilution), rabbit anti-H3S10ph (Abcam, Cambridge, MA; cat. no. 
ab5176, 1:1,000 dilution), rabbit anti-H3K14ac (Millipore, cat. no. 07-353, 1:2,000 
dilution), rabbit anti-H3K56ac (ActiveMotif, Carlsbad, CA; cat. no. 39281, 1:5,000 dilution) 
and rabbit anti-H4R3me2asym (Abcam, Cambridge, MA; cat. no. ab194683, 1:1,000 
dilution). Blots were processed using goat anti-mouse and anti-rabbit secondary 
antibodies from LI-COR Biosciences (both at 1:20,000 dilution) and imaged using an 
Odyssey Fc imaging system (LI-COR Biosciences). All immunoblotting experiments were 
independently repeated a minimum of three times. Densitometric analysis of Western 
blots was preformed using Image Studio (LI-COR Biosciences). The signals obtained for 
histone modifications were normalized to their respective total H3 signals 
(modification/total H3). These values were then compared with untreated control-sample 
values to obtain fold change values (sample/control), which were used for statistical 
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analysis. Similarly, FUS bands were compared to Phosphoglycerate Kinase-1 signal 
values for normalization.  
Filter Retention Assay Filter retention assay procedures were modified from Alberti et 
al., 2010.224 Briefly, cells were incubated in spheroblasting solution [1. M D-Sorbitol, 0.5 
mM MgCl2, 20 mM Tris - pH 7.5, 50 mM b-mercaptoethanol, 0.5 mg/mL zymolase 
(Nacalai Tesque, Kyoto, Japan; cat. no. 07663-91)] for 1 hours at 30 °C while rotating. 
The samples were then centrifuged at 800 rcf for 5 min and the supernatant was removed. 
The pellets were then resuspended with in 180 µL of lysis buffer [20 mM Tris – pH 7.5, 
10 mM b-mercaptoethanol, 0.5% Triton X-100, 2X HALT Protease Inhibitor (Thermo 
Scientific, Waltham, MA; cat. no. 78425)] and incubated at room temperature for 10 
minutes. The sample was then centrifuged at 21,130 rcf for 2 minutes and 60 µL of the 
supernatant was added to the well of 96-well plate, in triplicate. 80 µL of sterile distilled 
water was added to the well of each plate. The Bio-Dot vacuum manifold (Bio Rad, 
Hercules, CA) was assembled according to manufacturer’s instructions after the cellulose 
acetate membrane was soaked in PBS. Any unused wells were covered with tape to 
increase vacuum pressure. 100 µL of sample were loaded into wells of the apparatus and 
allowed to gravity filter, followed by the addition of 200 µL PBS and gravity filtration. 200 
µL of blocking buffer (LI-COR Biosciences) were added and allowed to gravity filter and 
then washed twice with 200 µL PBS, which were vacuum filtered. 100 µL of FUS primary 
antibody (Bethyl Laboratories, 1:1,000 dilution) was then added and allowed to gravity 
filter, followed by three PBS washes which were vacuum filtered. Finally, 100 µL of 
secondary antibody was added (anti-rabbit, LI-COR Biosciences, 1:20,000 dilution) and 
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allowed to gravity filter, followed by two PBS washes which were vacuum filtered. The 
blot was imaged using an Odyssey Fc imaging system (LI-COR Biosciences). 
Statistical Analysis Statistical analysis of data was performed in RStudio 1.2.5001 using 
the built-in stats package (R-Project, Vienna, Austria). Significant differences between 
drug treatment groups were determined using one-way ANOVA followed by Tukey’s test 
for pairwise comparison of the group means with p = 0.05 as the cutoff for significance. 
Error bars on the graphs represent standard deviation (SD) calculated from values 
obtained in the data analysis steps described above. All graphs were constructed with 







Figure 17. Trichostatin A relieves growth suppression in a FUS ALS yeast model. 
Yeast integrated with a gene encoding FUS or an empty vector were serially diluted 5-
fold and spotted on glucose (off) or galactose (on) medium in the absence (untreated, 
DMSO) or presence of TSA at varying concentrations. Densitometric measurement of 
cell density compared to the untreated control is depicted. Box plot whiskers represent 






Figure 18. Trichostatin A relieves growth suppression in DPDR yeast 
overexpressing FUS. DPDR yeast integrated with a gene encoding FUS or an empty 
vector were serially diluted 5-fold and spotted on glucose (off) or galactose (on) medium 
in the absence (untreated, DMSO) or presence of TSA at varying concentrations. 
Densitometric measurement of growth compared to the untreated control is depicted. Box 
plot whiskers represent upper and lower quartiles and dot represents an outlying data 





Figure 19. Trichostatin A has no effect on FUS expression or aggregation. FUS 
expression was measured by Western blotting (A, n = 4), while FUS aggregation was 
measured with a filter retention assay (B, n = 6). Histograms compiling multiple biological 
replicates display the mean fold change in FUS expression or aggregation based on 






Figure 20. Trichostatin A restores acetylation on Lysines 14 and 56 on Histone H3 
in the yeast FUS ALS model. Representative Western blots displaying the levels of 
H3K14ac (A, n = 6) and H3K56ac (B, n = 6) are shown. Histograms compiling multiple 
biological replicates are shown alongside blots. Error bars represent +SD. * = p < 0.05, 





Figure 21. Trichostatin A treatment has no effect on H4K16ac levels in the yeast 
FUS ALS model. A representative Western blot displaying the levels of H4K16ac (n = 
6) is shown. A histogram compiling multiple biological replicates is also shown. Error 




Figure 22. Trichostatin A has no effect on histone acetylation levels on Histone H3 
K14 and K56 in vector control yeast. Representative Western blots displaying the 
levels of H3S10ph (a, n = 3) and H3K56ac (b, n = 4) are shown. Histograms compiling 




Figure 23. Trichostatin A has no effect on H3S10ph or H4R3me2asym levels in the 
yeast FUS ALS model. Representative Western blots displaying the levels of H3S10ph 
(a, n = 3) and H3K56ac (b, n = 4) are shown. Histograms compiling multiple biological 





Figure 24. Trichostatin A has no effect on H3S10ph or H4R3me2asym levels in 
vector control yeast. Representative Western blots displaying the levels of H3S10ph (a, 
n = 3) and H4R3me2asym (b, n = 3) are shown. Histograms compiling multiple biological 









Chapter 4: FUS binds directly binds Nop1 while Ipl1 and Rtt109 are 
mislocalized leading to dysregulation of histone post-translational 
modification and reduced levels of total RNA. 
4.1 Rationale  
 We have previously reported that various histone PTMs are significantly depleted 
in FUS proteinopathy yeast model (Chapter 2),73 and that restoring histone acetylation 
via chemical intervention rescues the growth suppression phenotype elicited by FUS 
overexpression (Chapter 3). In this Chapter, we explore how FUS overexpression and 
aggregation impacts the histone PTM landscape. To accomplish this, we interrogated 
the FUS interactome in a yeast proteinopathy model by way of co-immunoprecipitation 
(Co-IP) coupled to mass spectrometry (MS)-based proteomics. FUS is a RNA-binding 
protein, that is primarily located in the nucleus and is involved numerous cellular 
processes including RNA maturation and DNA repair.160, 226 We hypothesize that FUS is 
sequestering chromatin proteins and leading to a loss of function, and ultimately 
reducing levels of H3S10ph, H3K14ac, H3K56ac and H4R3me2asym.  
 In a separate approach, we probed for the levels and cellular localization of those 
histone modifying enzymes responsible for deposition of histone PTMs connected to 
FUS proteinopathy. In particular, we studied Ipl1, Gcn5 and Rtt109, which are 
responsible for the deposition of H3S10ph, H3K14ac and H3K56ac, respectively.176, 215, 
216, 221 We added a Flag tag to the C-terminal end of these enzymes by PCR targeting 
and measured their levels and localization by Western blotting and 
immunocytochemistry (ICC), respectively.  
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 Lastly, we investigated if RNA binding by FUS is necessary for dysregulation of 
histone PTMs. A FUS construct with point mutations in its RNA Recognition Motifs (FUS 
RRM) that obliterate RNA binding was overexpressed in yeast. FUS RRM is less toxic 
compared to wild-type FUS.160 We measured the levels of H3S10ph, H3K14ac, 
H3K56ac and H4R3me2asym in yeast overexpressing FUS RRM by Western blotting 
and compared them to yeast overexpressing wild-type FUS or a vector control. 
 Here we show that FUS binds a large number of proteins in yeast, including the 
histone methyltransferase Nop1. Furthermore, Ipl1 and Rtt109 are significantly 
mislocalized from the nucleus. Interestingly, Ipl1 colocalizes with FUS. Lastly, we find 
that it is not necessary for FUS to bind RNA for it to elicit dysregulation of PTMs. FUS 
RRM elicits a similar reduction in the levels of H3S10ph, H3K14ac, H3K56ac and 
H4R3me2asym as wild-type FUS. Altogether, we present a model where Ipl1 and FUS 
are mislocalized to the cytoplasm in FUS yeast from the nucleus, causing the reduction 
of histone PTM levels, and these decreased PTMs and FUS-Nop1 binding lead to lower 
total RNA levels. 
4.2 FUS Co-IP Assay 
4.2.1 Putative binding partners of FUS are involved in ATP binding and rRNA 
processing 
 To gain insight into the molecular mechanisms connecting protein 
aggregation to histone modification changes, we interrogated FUS’ protein interactome 
in yeast by performing a Co-immunoprecipitation experiment (Co-IP) using a FUS 
antibody as the bait (Figure 26a). A rabbit polyclonal FUS antibody was covalently 
attached to magnetic beads and incubated with lysates from yeast overexpressing FUS. 
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As a negative control, we incubated beads conjugated to the FUS antibody with lysates 
from yeast overexpressing a vector control. This control accounts for non-specific 
protein binding to the FUS antibody. As an additional negative control, we also 
incubated non-conjugated “naked” beads with FUS yeast lysates to control for non-
specific binding to the beads themselves. The recovered proteins were separated by 
SDS-PAGE and visualized by Silver staining (Figure 27a). There are a number of 
distinct protein bands in the FUS lane, while the two control lanes are relatively devoid 
of protein. In the FUS sample, there is a prominent band near the 34 kDa molecular 
weight marker. Another band between the 43 and 55 kDa molecular weight markers is 
also present. The strong band around 55 kDa is likely FUS itself. We confirmed FUS 
pulldown via Western Blotting (Figure 27b).  
 To identify FUS’ binding partners, recovered proteins from two independent Co-
IP experiments were analyzed by tandem MS. Each trial identified over 2,000 proteins 
to interact with FUS. To narrow down proteins of interest, we only considered proteins 
that: (1) were among the hits in both trials, (2) had over 40 peptide spectrum matches in 
the FUS Co-IP condition, and (3) displayed at least two-fold enrichment over the two 
control conditions. A peptide spectrum match refers to the number of times a peptide is 
identified, and relates to the abundance of a particular protein in the sample.227 This 
filtering process rendered 39 proteins as putative FUS binding partners (Figure 26b; 
Table 3). Interestingly, we do not observe Ipl1 or Rtt109 as putative binding partners of 
FUS, suggesting that their sequestration to the cytoplasm is not due to direct interaction 
between these proteins.  
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To better understand what cellular functions FUS proteinopathy impacts, we 
submitted our final 39 proteins for pathway analysis with the online tool DAVID.228, 229 
The resulting Gene Ontology230 and KEGG 231-233 Pathway annotations are shown in 
Table 4. Three of the four top GO biological annotations are involved in rRNA 
processing, while the top three molecular function annotations are involved in ATP 
binding. Interestingly, a large number of ribosomal proteins were identified as FUS 
partners in a GST tagged FUS Co-IP study in 293T cells.234 Using the resulting 
annotations, we created an enrichment map Figure 26c. The nodes in the map 
represent annotations that were significantly over-represented in the 39 putative binding 
proteins, and the nodes were automatically clustered into similar biological processes. 
Out of 17 nodes, 11 were related to ATP binding Figure 26c, yellow oval. Interestingly, 
many of the nodes that correspond to ATP binding are related to ATP-dependent RNA 
helicase activity. Furthermore, six putative binding proteins (Dbp1, Dbp2, Ded1, Mcm4, 
Prp43 and Ylr419W) are RNA helicases.235-239 Unsurprisingly, we also find the ATP 
binding subunits of Hsp70 chaperone (Ssa1 and Ssa2) among our protein hits.240 FUS 
is found in cytoplasmic aggregates and Hsp70 may be present to process such 
aggregates. Furthermore, the translational initiation factor Tef1 is also among our 
hits.241 Interestingly, Tef1 has a molecular weight of 50 kDa and correspond to the 
strong band observed on the Silver stain of the FUS Co-IP between 43 and 55 kDa 
(Figure 27). FUS proteinopathy is associated with decreased gene expression, and 
Tef1 binding by FUS and nuclear exclusion might contribute to this. The other six nodes 
are associated with rRNA processing (Figure 26c, teal oval). Five putative FUS binding 
proteins are in each of these six nodes; Utp10, Nop56, Rrp5, Utp22 and Nop1. Rrp5 is 
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an RNA binding protein involved in 18S and 5.85S rRNA biogenesis.242 Nop56 is a 
nucleolar protein that directs the methylation of pre-rRNA.243 Utp10 and Utp22 are both 
members of the small-subunit processome, with the former being involved in the 
processing of pre-18SrRNA and the latter being necessary for the export of tRNAs from 
the nucleus.244, 245  
4.2.2 Nop1 is a FUS binding partner. 
 We next wanted to identify the distinct 34 kDa band on the silver stain (Figure 
27). Out of the 39 proteins of interest, two proteins have molecular weights in the 34 
kDa range, Pet9 and Nop1. Pet9 transports ADP from the cytosol to the mitochondria 
and ATP in the reverse direction.246 Nop1, the yeast homologue of fibrillarin, is a histone 
modifying enzyme that responsible for the methylation of H2AQ105 and involved in the 
transcription of rRNA.247, 248 We decided to focus on Nop1 as it relates more directly to 
the histone PTM landscape and is involved ribosomal production and processing.245, 249  
To verify that FUS binds Nop1, we conducted a FUS Co-IP experiment as 
described above, but the recovered proteins were separated by SDS-PAGE followed by 
blotting against a Nop1 antibody. The total input was used a positive control and both 
control and FUS yeast show Nop1 bands (Figure 28a, lanes 1 and 2). As a negative 
control, FUS yeast were incubated with unconjugated beads. We did not observe any 
Nop1 binding to naked beads (Figure 28a, lane 3). Importantly, only FUS yeast showed 
Nop1 in the Co-IP condition (Figure 28a, lanes 4 and 5). PGK1 was used as a loading 
control, and was only present in the input lanes (Figure 28a, lanes 1 and 2). On top of 
our proteomic findings, these results provide further evidence that FUS and Nop1 are 
interacting directly. For additional confirmation of this interaction, we performed a 
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reverse Co-IP experiment using a Nop1antibody as the bait and probing for FUS via 
immunoblotting. We first validated the Nop1 antibody pulls down Nop1 (Figure 28b). 
Next, we probed the recovered proteins for FUS (Figure 28c). Expectedly, the input 
control only showed FUS in FUS yeast (Figure 28c, lanes 1 and 2) and there is no FUS 
signal in yeast incubated with unconjugated beads (Figure 28c, lane 3). We detect FUS 
in the Nop1 reverse Co-IP condition in FUS yeast while control yeast showed no FUS 
(Figure 28c, lanes 4 and 5). Finally, we visualized Nop1 and FUS in control and FUS 
yeast via immunocytochemistry (Figure 28d). In both control and FUS yeast we 
observed strong Nop1 staining centered in the nucleus (Figure 28d, first column). As 
before, we observe no FUS staining in control yeast and strong cytoplasmic puncta in 
FUS yeast (Figure 28d, second column). Importantly, we see yellow puncta in the 
merge, evidencing colocalization between FUS and Nop1 (Figure 28d, white arrows). 
These results confirm the interaction between FUS and Nop1 and suggest that FUS is 
tied to partial redistribution of Nop1.	Furthermore, it provides mechanistic insight into 
FUS pathology in the proteinopathy yeast model as FUS-Nop1 binding may impede 
Nop1 function and reduction in rRNA.  
4.3 Expression levels and cellular localization of histone modifying enzymes 
4.3.1 Expression levels of histone modifying enzymes are unchanged in FUS 
yeast 
FUS proteinopathy is connected to changes in H3S10ph, H3K14ac, H3K56ac 
levels. These modifications are installed by the enzymes Ipl1, Gcn5 and Rtt109, 
respectively. It is possible changes on histone PTM arise from changes in the levels in 
the histone modifying enzymes themselves. Unfortunately, this possibility cannot be 
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directly tested via immunoblotting as there are no commercially available antibodies for 
these enzymes. To circumvent this problem, we attached a Flag tag to the C-termini of 
the Ipl1, Gcn5 and Rtt109 genes via PCR targeting.250 Inserts were created with primers 
containing the genomic sequence of each enzyme and the 3X Flag – KanMX region of 
the pTF270 plasmid (Table 5, Figure 29a). The resulting DNA insert was transformed 
into control and FUS yeast using a high efficiency transformation protocol. Insertion was 
verified by selection against G418 as well as PCR using forward primers recognizing 
the gene of interest and a universal primer recognizing the Flag region of the insert 
(Figure 29b).  
 To measure the expression levels of Ipl1, Gcn5, and Rtt109, we overexpressed 
FUS and the vector control in PCR-targeted yeast. We did not observe any differences 
in histone modifying enzymes between FUS and control yeast (Figure 30). These 
results suggest that dysregulation of histone PTMs is not caused by a reduction in the 
levels of the enzymes responsible for their deposition. 
 
4.3.2 Cellular Localization of FLAG-tagged histone modifying enzymes 
 As the levels of Ipl1, Gcn5 and Rtt109 were not impacted by FUS proteinopathy, 
we wanted to explore whether their cellular localization was changed in this context. We 
preformed immunocytochemistry (ICC) on FUS and control yeast that were transformed 
with either Ipl1-Flag, Gcn5-Flag or Rtt109-Flag. We calculated the percent of nuclear 
localization for FLAG-tagged proteins,251 and measured Colocalization with the Manders 
Colocalization Coefficient (MCC).252 This measurement calculates the numbers of pixels 
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that overlap between two fluorescently labeled images.253 The MCC measurement is 
between 0 and 1, where number represents the percentage of overlap.  
4.3.2.1 Gcn5 is not significantly depleted from the nucleus 
 FUS and control yeast transformed with Gcn5-FLAG were imaged (Figure 31). 
Expectedly, we do not see any staining for FUS in control yeast, whereas FUS yeast 
display robust staining in the cytoplasm (Figure 31a). There is diffuse FLAG staining 
throughout the cells with distinct puncta in both control and FUS yeast (Figure 31a). We 
did not observe any difference between the percent nuclear FLAG staining between 
control and FUS yeast, suggesting Gcn5 is not mislocalized in response to FUS (Figure 
31b). We did not observe yellow puncta in the in the “Merge” images in FUS yeast 
(Figure 31a), suggesting there is no colocalization between Gcn5-FLAG and FUS. The 
MCC measurements validated this, displaying and MCC of ~0.5, meaning that only 50% 
of FLAG and FUS overlap (Figure 31c). 
4.3.2.2 Rtt109 is mislocalized to the cytoplasm in FUS yeast 
 We imaged FUS and control yeast transformed with Rtt109-FLAG (Figure 32). 
As before, we do not detect any staining for FUS in the control yeast, whereas FUS 
yeast display robust staining in the cytoplasm (Figure 32a). There is diffuse FLAG 
staining in the throughout the cells with distinct puncta in both control and FUS yeast 
(Figure 32a). Remarkably, the percentage of nuclear FLAG staining is significantly 
lower in FUS yeast compared to control (Figure 32b), suggesting that lowered 
H3K56ac levels may be caused by nuclear exclusion of Rtt109. Similar to Gcn5-FLAG 
FUS yeast, we did not observe yellow puncta in Rtt109-FLAG FUS “Merge” image 
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(Figure 32a). Colocalization analysis returned averaged MCC value of ~0.55, meaning 
only 55% of FUS and FLAG overlap.  
4.3.2.3 Ipl1 is mislocalized from the nucleus and colocalizes with FUS 
 We imaged FUS and control yeast transformed with Ipl1-FLAG (Figure 33). 
Again, we do not see any staining for FUS in control yeast, whereas FUS yeast display 
robust staining in the cytoplasm (Figure 33a). There is diffuse FLAG staining 
throughout the cells with distinct puncta in both control and FUS yeast (Figure 33a). 
Excitingly, the percentage of nuclear FLAG staining is significantly lower in FUS yeast 
compared to control (Figure 33b), suggesting that lowered H3S10ph levels may be 
caused by nuclear exclusion of Ipl1. Interestingly, we observe yellow puncta in FUS Ip1-
FLAG yeast, suggesting colocalization between the two fluorophores. (Figure 33a, 
yellow arrows). Colocalization analysis calculated an average MCC value of ~0.75, 
meaning that 75% of Ipl1-FLAG is overlapping with FUS (Figure 33c). These results 
support the hypothesis that cellular mislocalization of Ipl1 is causing the decreased the 
levels of H3S10ph in FUS yeast. However, the exact interaction between FUS and Ipl1 
remain unclear. The colocalization between the two proteins suggest that Ipl1 is being 
sequestered, but our Co-IP results not reveal any direct binding between the two. 
4.3.3 Ipl1, Gcn5 and Rtt109 do not bind FUS or Nop1directly 
As we observed co-localization between Ipl1 and FUS (Figure 33), but Ipl1 was absent 
from our FUS partners proteomic hits, we wondered if Ipl1 interacted with FUS indirectly 
via Nop1. We investigated if Ipl1-FLAG was directly interacting with FUS or Nop1 using 
the same Co-IP scheme described above. We first confirmed that the FUS Co-IP is 
pulling down FUS in yeast expressing Ipl1-FLAG (Supplementary Figure 34a). Next, 
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we confirmed that FUS interacts with Nop1 in yeast expressing Ipl1-FLAG 
(Supplementary Figure 34b). We then performed a reverse Co-IP using a Nop1 
antibody as bait and confirmed that Nop1 pulled down Nop1 in yeast expressing Ipl1-
FLAG (Supplementary Figure 34c) and that Nop1 pulls down FUS in yeast expressing 
Ipl1-FLAG (Supplementary Figure 34d). We also confirmed that FUS and Nop1 are 
interacting in Gcn5-FLAG (Figure 35) Rtt109-FLAG (Figure 36) yeast. We then 
analyzed recovered proteins from the FUS and Nop1 Co-IPs by probing for FLAG in 
Ipl1-FLAG (Figure 37a,b), Gcn5-FLAG (Figure 37c,d) and Rtt109-FLAG (Figure 37e,f) 
yeast. The FLAG tag was detected in lysates of control and FUS yeast, but did not 
appear in any of the Co-IP conditions (Figure 37a-f). Thus, we conclude that Ipl1 is not 
directly interacting with FUS or Nop1, and that it is colocalizing with FUS through an 
interaction with another binding protein. Similarly, the lack of interaction between Gcn5 
or Rtt109 with FUS or Nop1 suggest that the reduced levels are H3K14ac and H3K56ac 
are not caused by sequestration of these respective histone modifying enzymes. 
4.4 FUS-RNA binding does not contribute to histone PTM dysregulation 
4.4.1 FUS RRM yeast display reduced growth suppression 
 Next, we investigated if RNA binding by FUS contributes to dysregulation of 
histone PTMs. Mutating conserved phenylalanine residues to leucine (F305L, F341L, 
F359L, F368L) in the RRM domains abolish FUS’ ability to bind RNA.160 FUS with these 
mutations in the RRM domain (hence forth referred to as RRM) still aggregates but is 
markedly less toxic.160 We transformed yeast with non-integrating plasmids containing a 
galactose inducible gene for FUS, RRM or a vector control. As previously reported,160 
FUS overexpression is still very toxic, but growth suppression has mostly been 
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eliminated in RRM yeast (Figure 38a). To assure that the reduction of the growth 
suppression was due to the mutation and not a lack of FUS expression, we verified FUS 
expression via western blotting (Figure 38b).  
4.4.2 RNA binding is not necessary for histone PTM dysregulation 
 Levels of H3S10ph, H3K14ac, H3K56ac and H4R3me2asym were measured in 
FUS, RRM and control yeast as described in Chapter 2. Histone acetylation levels on 
H3K14 and H3K56 were significantly decreased for FUS and RRM compared to control 
(Figure 39a,b). We did not observe a statistical difference in the levels of these two 
PTMs between FUS and RRM yeast. Similarly, we observed a significant reduction in 
H3S10ph and H4R3me2asym levels in FUS and RRM yeast compared to the control, 
with no difference between FUS and RRM yeast (Figure 40a,b). These results support 
that dysregulation of histone PTMs is independent of FUS’ ability to bind RNA. 
 As discussed in Chapter 2, these dysregulated PTM are involved in active gene 
expression.73 We measured total RNA levels in the FUS, RRM and control yeast to test 
if there is a decrease transcription. Unsurprisingly, we observed an almost 50% 
decrease in total RNA in FUS and RRM yeast compared to control, with no difference 
between FUS and RRM yeast (Figure 41). These results further confirm that PTM 
dysregulation and its impact on gene expression is independent of FUS-RNA binding.  
4.5 Conclusions 
 Altogether, we find that histone PTM dysregulation is independent of FUS-
RNA binding in a FUS yeast overexpression model. In this context, we also show that 
the enzyme modifiers Ipl1 and Rtt109 mislocalize to the cytoplasm explaining the 
decrease in the H3S10ph and H3K56ac marks. In contrast, the histone 
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acetyltransferase Gcn5 is not redistributed in the context of FUS overexpression. Thus, 
we speculate that reduction in H3K14ac is occurring via histone crosstalk. Indeed, 
H3S10ph has been previously shown to drive H3K14ac.254 However, we cannot exclude 
the possibility that increased HDAC activity is leading to the loss of H3K14ac. 
Remarkably, Ipl1 colocalizes with FUS, but it absent from our interactome results and 
thus we believe it does not bind FUS directly. Interestingly, Rrp5, an RNA-binding 
protein among our FUS binding partner results, has been found to associate with 
Ipl1.255, 256 It is possible that Rrp5 binds to both FUS and Ipl1, and serves as the bridge 
between these two proteins. However, further investigation is needed to definitely 
establish this scenario.  
We also establish that FUS directly binds Nop1. Nop1 has been identified as the 
methyltransferase responsible methylation of H2AQ105, a histone mark linked to the 
recruitment of RNA Polymerase I and rRNA biogenesis.248 Unfortunately, we are not 
able to measure the levels of H2AQ105me in our FUS yeast as there is no commercially 
available antibody for this modification. Intriguingly, recruitment of Nop1 to rDNA is 
dependent on H3K56ac.257 Dysregulation of H3K56ac and FUS-Nop1 binding suggest 
that decreased rRNA biogenesis could be contributing to FUS toxicity in yeast models. 
Strengthening this hypothesis, FUS has been implicated in the response to DNA 
damage caused by topoisomerase-I. FUS localizes to sites of stalled RNA Polymerase I 
to modulate rRNA biogenesis.258 Moreover, fibroblasts harvested from FUS ALS 
patients are hypersensitive to topoisomerase-I DNA damage, suggesting a role for 
rRNA biogenesis in ALS.  
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Our working model involves Ipl1 being sequestered from the nucleus through 
indirect interaction with FUS leading to reduced levels of H3S10ph. In a parallel 
mechanism, Rtt109 mislocalization leads to the decrease of H3K56ac levels. We 
postulate that H3K14ac levels are lowered through histone crosstalk with H3S10ph. In 
sum, histone PTM dysregulation and direct interaction between FUS and Nop1 results 
in reduced gene expression and negative cellular outcomes in the context of FUS 
proteinopathy. These mechanisms appear to be independent of FUS’ ability to bind 
RNA. A schematic representation of the mechanisms linking FUS proteinopathy to the 
epigenome is shown in Figure 42. 
Our studies agree with previous findings in various ALS/FTD model systems. 
Furthermore, our results shed some light into the mechanisms linking protein 
aggregation to negative cellular outcomes, and highlight the role of histone PTMs and 
histone modifiers in disease processes. While it is important to note that our studies are 
limited to yeast models, and thus, verification in other model systems is still necessary, 
our results underscore histone modifiers as potential targets for pharmaceutical 
intervention in the treatment of ALS. Novel chemical intervention strategies aimed at 
histone modifiers such Aurora B kinase p300/CBP could potentially improve cell survival 
in the context of neurodegenerative disease. Our investigation also enables several 
interesting questions. For instance, how is Rtt109 is ejected from the nucleus?  It is 
possible that nucleocytoplasmic transport defects elicited by FUS are excluding Rtt109 
from the nucleus,259 but again, further investigation is required. Furthermore, how do 
identified FUS binding partners contribute to FUS pathology? Of particular interest is the 
RNA-binding protein Rrp5 and its possible role in the interaction between FUS and Ipl1. 
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Lastly, what is the role of rRNA biogenesis in ALS? Recent evidence has revealed the 
FUS is recruited to rDNA after DNA damage caused by topoisomerase-I, and FUS 
aggregation and export from the nucleus may be preventing this repair mechanism and 
contribute to ALS/FTD pathology.258 
 Specific histone PTM alterations are tied to FUS proteinopathy, though the 
molecular mechanisms behind this association are unclear. We illuminate direct and 
indirect interactions connecting protein aggregation to the epigenome. We have shown 
that FUS does not need to bind RNA to elicit changes in histone PTMs. Furthermore, 
FUS proteinopathy is linked to mislocalization of the histone kinase Ipl1 and histone 
acetyltransferase Rtt109 to the cytoplasm, leading to reduction of H3S10ph and 
H3K56ac levels. In contrast, the levels and the cellular localization of the histone 
acetyltransferase Gcn5 is unchanged; H3K14ac might be lowered through histone 
crosstalk. We establish that FUS directly binds the histone modifier Nop1. Dysregulation 
of H3S10ph, H3K14ac and H3K56ac as well as FUS binding to Nop1 are potentially 
contributing to reduced gene expression and FUS cytotoxicity. Our results highlight the 
contribution of histone PTMs and histone modifiers to ALS and other neurodegenerative 
diseases and reveal novel targets for therapeutic intervention. 
4.6 Experimental methods 
Yeast Strains, Media and Plasmids All yeast were W303a (MATa, can1-100,his3-11, 
15,leu2,3,11,12,trp1-1,ura3-1,ade2-1).90 Yeast were grown in synthetic dropout medium 
(Clonetech Laboratories, Mountain View, CA) supplemented with 2% glucose, raffinose 
or galactose. The integrating FUS plasmid (pAG303GAL-FUS) was a gift from A. Gitler 
(Addgene plasmid no. 29614).92 A control integrating ccdB plasmid, pAG3030GAL-ccdB, 
 87 
was a gift from Susan Lindquist (Addgene plasmid no. 14133).90 The non-integrating 
plasmids 426Gal-FUS-RRM-YFP (Addgene plasmid no. 29608), 426Gal-FUS-YFP 
(Addgene plasmid no. 20592) and paG426Gal-ccdB (Addgene plasmid no. 14155) were 
gifts from A. Gitler and Susan Lindquist, respectively. Yeast were transformed using 
standard poly(ethylene glycol) and lithium acetate protocols.222  
Transformation of yeast with FLAG-tag histone modifying enzymes via PCR 
targeting We designed primers recognizing the FLAG and KanMX sequence in the 
pTF268 plasmid (Addgene plasmid no. 44095) in the 5’ and 3’ ends were created with 40 
base overhangs recognizing the end of either Ipl1, Gcn5 or Rtt109 up to stop codon 
(forward primer) and the immediate bases after the stop codon (reverse primer, Table 4). 
The primers were then used in a PCR reaction (Phusion High-Fidelity PCR Kit, New 
England BioLabs, Ipswich, MA, Cat. No. E0553L) using the pTF268 plasmid as a template 
to create transforming insert. The inserts were then used to transform FUS and control 
yeast using a high efficiency yeast transfer protocol.250 We selected for transformed 
colonies by plating yeast on synthetic dropout media plates containing 450 µg/mL G418. 
Homologous recombination with the target gene was confirmed by PCR using yeast 
lysate as the template with a forward primer recognizing an area of the gene of interest 
and a reverse primer recognizing the Flag sequence (Table 4). 
Protein Overexpression Yeast strains were grown to saturation overnight in raffinose-
supplemented dropout media at 30 °C and 200 rpm. Overnight cultures were then diluted 
to an OD600 of 0.30 in galactose-supplemented synthetic dropout media and grown for 5 
hours at 30 °C. Yeast cultures were then standardized to the lowest OD600. Cells were 
then pelleted at 850 rcf at 4 °C and washed 3x with sterile distilled water and harvested. 
 88 
The supernatant was removed and the pellets were flash frozen in liquid nitrogen and 
stored at -80 °C.  
Serial dilution growth assays Growth suppression for FUS RRM constructs was 
measured by spotting assay, yeast were grown to saturation overnight in raffinose-
supplemented dropout media at 30°C. Overnight cultures were diluted 2-fold, then serially 
diluted 5-fold. Yeast were spotted onto synthetic dropout medium containing glucose or 
galactose with a frogger. Yeast were grown for 3 to 4 days before imaging. 
Western blotting Frozen yeast cell pellets were thawed and treated with 0.2 M NaOH 
for 10 minutes on ice, pelleted again, and subsequently resuspended in 100 µL of 1x 
SDS sample buffer and boiled for 10 minutes. Cell lysates were separated using SDS-
PAGE and then transferred to a PVDF membrane (EMD Millipore). Membranes were 
blocked using LI-COR blocking buffer (LI-COR Biosciences, Lincoln, NE) for 1 hour at 
RT. Membranes were incubated with primary antibodies at 4 °C overnight. Primary 
antibodies used were: rabbit anti-FUS polyclonal (Bethyl Laboratories, Montgomery, TX; 
cat. no. A300-302A, 1:1,000 dilution), mouse anti-PGK monoclonal (Novex, Frederick, 
MD; cat. no. 459250, 1:2,000 dilution), mouse anti-H3 total (Abcam, Cambridge, MA; 
cat. no. ab24834, 1:2,000 dilution), rabbit anti-H3S10ph (Abcam, Cambridge, MA; cat. 
no. ab5176, 1:1,000 dilution), rabbit anti-H3K14ac (Millipore, cat. no. 07-353, 1:2,000 
dilution), rabbit anti-H3K56ac (ActiveMotif, Carlsbad, CA; cat. no. 39281, 1:5,000 
dilution), rabbit anti-H4R3me2asym (Abcam, Cambridge, MA; cat. no. ab194683, 
1:1,000 dilution), mouse anti-a-Tubulin (1:10,000), mouse anti-Flag M2 (cat. no. F3165) 
and mouse anti-Nop1 (Invitrogen, Waltham, cat. no. 28F2). Blots were processed using 
goat anti-mouse and anti-rabbit secondary antibodies from LI-COR Biosciences (both at 
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1:20,000 dilution) and imaged using an Odyssey Fc imaging system (LI-COR 
Biosciences). All immunoblotting experiments were independently repeated a minimum 
of three times. Densitometric analysis of Western blots was preformed using Image 
Studio (LI-COR Biosciences). The signals obtained for histone modifications were 
normalized to their respective total H3 signals (modification/total H3). These values 
were then compared with untreated control-sample values to obtain fold change values 
(sample/control), which were used for statistical analysis. Similarly, Flag bands were 
compared to a-Tubulin signal values for normalization. 
Co-Immunoprecipitation Control and FUS yeast were grown until an O.D. of ~0.8 and 
harvested by centrifugation at 850 rcf at 4 °C for 5 minutes, followed by washing two 
times with sterile water. The resulting pellet was spheroplasted by resuspension in 500 
µL of spheroplasting solution (1.2 M D-Sorbitol, 0.5 mM MgCl2, 20 mM Tris-pH 7.5, 50 
mM b-mercaptoethanol, 0.5 mg/mL Zymolyase-100T) with constant rotation at 30 °C for 
one hour, followed by harvesting at 800 rcf for 5 minutes at room temperature. The 
resulting pellet was then resuspended in 200 µL lysis buffer (20 mM Tris-pH 7.5, 10 mM 
b-mercaptoethanol, 0.5% Triton X-100, 2X HALT Protease Inhibitor) and incubated for 
10 minutes at room temperature, followed by centrifugation at 4000 rcf for 5 minutes. 
The resulting supernatant was used immediately for Co-IP. FUS or Nop1 antibodies 
were conjugated to M270 Dynabeads and the co-immunoprecipitation was completed 
using the Dynabeads Co-Immunoprecipitation Kit according to the manufacturer’s 
specifications using the highest stringency washes (Invitrogen, Waltham, MA, cat. no. 
14321D). Resulting proteins were analyzed via Western blotting. For samples analyzed 
by mass spectrometry, the bead-cell lysis slurry was washed four times with sterile 
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filtered PBS and submitted for MS analysis (NYU Proteomics Core). Briefly, the protein 
were digested on beads, by reducing with DTT at 57 °C for 1 hour followed by alkylation 
with Iodoacetmaide at room temperature for 45 minutes and digested with sequencing 
grade Trypsin overnight. The samples were then de-salted using a C-18 membrane and 
washed three times with 0.1% TFA. Samples were then eluted with 0.5% acetic acid 
and dried in a SpeedVac. The sample was then reconstituted in 0.5% acetic acid. The 
samples were then separated by LC using an EASY-nLC 1220 (ThermoScientific). 
Peptides were gradient eluted from the column directly to the Orbitrap Eclipse using a 1 
hour gradient (Solvent A: 2% acetonitrile, 0.5% acetic acid; Solvent B: 80% acetonitrile, 
0.5 acetic acid). High resolution full MS spectra were acquired with a resolution of 
240,000, an AGC target of 1,000,000, with a maximum ion time of 60 ms and a scan 
range of 400 to 1500 m/z. All MS/MS spectra were collected using the following 
instrument parameter: in the ion trap, AGC target of 2,000, maximum ion time of 18 ms, 
one microscan, 2 m/z isolation window, fixed first mass of 110 m/z and NCE of 27. 
MS/MS spectra were searched against a Uniprot Yeast database using Sequest within 
Proteome Discoverer 1.4. Proteins of interest were determined by considering any 
protein that overlapped in the two trials and had a PSM over 40 and was at least two-
fold enriched compared to the controls. 
Immunocytochemistry FUS and control yeast containing either Ipl1-Flag, Gcn5-Flag 
or Rtt109-Flag were imaged using a standard protocol.260 Briefly, cells were fixed for 15 
minutes at constant rotation in 1 mL 4% paraformaldehyde solution (Ted Pella, 
Reeding, CA, cat. no. 18501; in 0.1 M sucrose), followed by 2 washes in 1 mL KPO4 
and 1 wash with 0.1 M KPO4/1.2M sorbitol. Cells were the resuspended in 1 mL of 0.1 
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M KPO4. Yeast were then spheroplasted for 12~13 minutes in 0.1 M KPO4, 0.3 M b-
mercaptoethanol and 0.1 mg/mL Zymolase-100T, followed by two washes with 0.1 M 
KPO4, harvested by 1 minute centrifugation in a microcentrifuge. Cells were 
resuspended in 50 µL 0.1 M KPO4. 15 µL of cells were then adhered to Teflon coated 
slides that were coated with 0.1% poly-lysine (Epredia, Portsmouth, NH, cat. no. 86-
010) and the supernatant aspirated off. The slide was immediately submerged into ice 
cold methanol for 6 minutes, followed submersion into room temperature acetone, 
quickly air dried. The cells were then blocked for 30 minutes with 25 µL PBS-BSA (150 
µM Bovine Serum Albumin, 0.05 M KPO4, 0.15 M NaCl, 30 mM NaN3). The cells were 
then incubated with primary antibody overnight (1:400 for FUS, 1:100 for FLAG), 
followed by 5 washes with blocking buffer, 1.25 hours incubation with secondary 
antibody (anti-rabbit AlexaFluor-488, 1:500, anti-mouse AlexaFluor-586, 1:1000), 5 
washes with blocking buffer and finally two washed sterile filtered PBS. All volumes 
were 25 µL/ well and all steps after addition of secondary antibody took place in the 
dark. The cells were mounted with 5 µL Fluoromount-G Mounting Medium with DAPI 
(Invitrogen, Waltham, MA, cat. no. 00-4959-52). The slides were images on a Zeiss 
LSM 800 confocal microscope at 63x magnification using the DAPI, AF488 and AF55 
lasers. Laser intensity was kept constant between control and FUS samples. The 
resulting images were processed using ImageJ.261 Nuclear intensity was calculated 
from each image by thresholding the DAPI image until only the nucleus was in view, 
selecting the area and superimposing it over the FLAG channel and measuring the 
mean fluorescence intensity and area. Whole cell FLAG intensity was measured by 
 92 
thresholding the FLAG image until only the cells were in view, selecting the area and 
measuring. Cytoplasmic intensity was then calculated using the formula:251 
Cytoplasmic Intensity = (Whole Cell Mean x Whole Cell Area) – (Nuclear Mean x Nuclear area) 
and percent nuclear localization was calculation using the formula:251 
%Nuclear = Nuclear Intensity/(Cytoplasmic Intensity + Nuclear Intensity) 
FUS and Flag Colocalization was measured with the JACoP plugin for the FUS and 
Flag channels.252 The threshold for the images was set to 100 so only the puncta were 
selected for calculating MCC.	
Statistical Analysis Statistical analysis of data was performed in RStudio 1.2.5001 using 
the built-in stats package (R-Project, Vienna, Austria). Significant differences between 
nuclear intensity and histone modifying enzymes levels were determined using Welch’s t 
test with p = 0.05 as the cutoff. Significant differences between FUS, RRM and control 
groups were determined using one-way ANOVA followed by Tukey’s test for pairwise 
comparison of the group means with p = 0.05 as the cutoff for significance. Error bars on 
the graphs represent standard deviation (SD) calculated from values obtained in the data 
analysis steps described above. All graphs were constructed with ggplot2 in RStudio (R-
Project, Vienna, Austria).225 
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Table 3. Putative FUS Binding Partners. 
Gene 
Symbol 






ACC1 Acetyl-CoA Carboxylase Q00955 250.2 
BEM2 Rho GTPase Activating Protein P39960 245.3 
DBP1 ATP-dependent RNA helicase P24784 112.9 
DBP2 ATP-dependent RNA helicase P24783 61 
DED1 ATP-dependent RNA helicase P06634 65.5 
FAS2 Fatty acid synthase P19097 206.8 
HHF1 Histone H4 P02309 11.4 
HSC82 Cytoplasmic chaperone – Hsp90 P15108 80.8 
MCM4 Helicase component of MCM  P30665 104.9 
MSS116 Transcription elongation factor P15424 76.2 
MYO2 Type V myosin motor P19524 180.6 
NOP1 Histone methyltranserfase P15646 34.4 
NOP56 C/D snoRNP complex component Q12460 56.8 
OLA1 P-loop APTase P38219 44.1 
PAB1 Poly(A) binding protein P04147 64.3 
PET9 Mitochondrial ADP/ATP carrier P18239 34.4 
PMA1 P2-type H+ ATPase P05030 99.6 
PMA2 P2-type H+ ATPase P19657 102.1 
PRP43 RNA helicase P53131 87.5 
RPO21 RNA polymerase II subunit P04050 191.5 
RRP5 RNA binding protein Q05022 193 
SAM1 S-adenosylmethionine synthase P10659 41.8 
SAM2 S-adenosylmethionine synthase P19358 42.2 
SSA1 Nuclear transport ATPase – Hsp70 P10591 69.6 
SSA2 Hsp70 ATP-binding protein P10592 69.4 
SSB2 Ribosome chaperone ATPase P40150 66.6 
TCB1 Lipid-binding ER protein Q12466 133.5 
TCB3 Cortical ER protein Q03640 171 
TEF1 Translational elongation factor P02994 50 
TOR1 Kinase subunit of TORC1 P35169 281 
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TY1A-OL Structural constituent of VLPs Q92392 49 
TY1B-
PR1 
Polyprotein processed to make 
Gag, RT, PR and IN 
P0C2I9 198.4 
URA2 Carbamoylphosphate synthetase P07259 244.9 
UTP10 Component of small subunit 
processome 
P42945 200 
UTP22 Component of small subunit 
processome 
P53254 140.4 
VPS1 GTPase required or vacuolar 
sorting 
P21576 78.7 
YHB1 Nitric oxide oxioreductase P39676 44.6 
YHR020W Prolyl-tRNA synthetase P38708 77.3 




Table 4. Gene Ontology and KEGG Pathway terms associated with putative FUS 
              binding proteins. 
GO Biological Pathway 
Term P-Value 
GO:0006364: rRNA processing 3.50E-04 
GO:0031167: rRNA methylation 5.80E-04 
GO:0010501: secondary structure unwinding 7.10E-04 
GO:0042254: ribosome biogenesis 1.80E-03 
GO:0006556: S-adenosylmethionine biosynthetic process 2.00E-02 
GO:0090344: negative regulation of cell aging 2.00E-02 
GO:0000451: rRNA 2'-O-methylation 2.60E-02 
GO:0042759: long-chain fatty acid biosynthetic pathway 2.60E-02 
GO:0006885: regulation of pH 3.30E-02 
GO:0090158: endoplasmic reticulum membrane organization 3.90E-02 
GO:0000390: spliceosomal complex disassembly 3.90E-02 
GO:0006413: translational initiation 4.30E-02 
GO:0006555: methionine metabolic process 4.60E-02 
GO:0060304: regulation of phosphatidylinositol dephosphorylation 4.60E-02 
GO:0051453: regulation of intracellular pH 5.20E-02 
GO:0010468: regulation of gene expression 7.70E-02 
GO:0000462: maturation of SSU-rRNA from tricistronic rRNA transcript 8.10E-02 
GO:0006409: tRNA export from the nucleus 8.90E-02 
GO:0030490: maturation of SSU-rRNA 9.50E-02 
GO Molecular Function 
Term  P-Value 
GO:0005524: ATP binding 1.60E-09 
GO:0000166: nucleotide binding 1.90E-09 
GO:0004004: ATP-dependent RNA helicase activity 1.00E-05 
GO:0003729: mRNA binding 7.00E-05 
GO:0004386: helicase activity 1.00E-04 
GO:0016887: ATPas activity 3.80E-04 
GO:0003676: nucleic acid binding 1.30E-03 
GO:0003723: RNA binding 9.30E-03 
GO:0046872: metal ion binding 1.00E-02 
GO:0030515: snoRNA binding 1.10E-02 
GO:0005544: calcium-dependent phospholipid binding 1.50E-02 
GO:0004478: methionine adenosyltransferase 1.50E-02 
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GO:0033592: RNA strand annealing activity  2.30E-02 
GO:0051082: unfolded protein binding 2.40E-02 
GO:0016787: hydrolase activity 2.70E-02 
GO:0008553: hydrogen-exporting ATPase activity, phosphorylative 
mechanism 3.80E-02 
GO Cellular Component 
Term P-Value 
GO:0010494: cytoplasmic stress granule 2.20E-05 
GO:0005739: mitochondrion 4.00E-05 
GO:0030686: 90S preribosome 1.50E-04 
GO:0032040: small-subunit proccessome 3.30E-04 
GO:0005886: plasma membrane 3.00E-03 
GO:0005654: nucleoplasm 3.00E-03 
GO:0000329: fungal-type vacuole membrane 1.10E-02 
GO:0005844: polysome 1.80E-02 
GO:0005737: cytoplasm 1.90E-02 
GO:0036464: cytoplasmic ribonucleoprotein granule 2.60E-02 
GO:0031428: box C/D snoRNP complex 3.80E-02 
GO:0005832: chaperonin-containing T-complex 6.90E-02 
GO:0005730: nucleolus 9.70E-02 
KEGG Pathway 
Term P-Value 
sce03400: Spliceosome 7.10E-03 
sce04141: Protein processing in endoplasmic reticulum 5.30E-02 





Table 5. Primers used in the PCR Targeting study. 









Ipl1-Flag Forward GATACTAAGAAACAAGCCCTTTTGGGAAAATAAGCGGTTAGGTGGAGGCTCTAGAGACTA 
Reverse TCGATGCTACATACGTGTACTAAATAATAAATATCAATATGTATCATTAAACTGGATGGCGGCGTT 
Primers Used for Insert Verification 
Universal Reverse TTAAACTGGATGGCGGCGTT 
Gcn5 Forward GCCGAATGTACAATGGCGAG 
Rtt109 Forward AAATCAGCCGGTTCCTGCAA 
Ipl1 Forward TAGAATGCGCCTTGGAGACG 






Figure 26. Putative binding partners of FUS are involved in rRNA processing and 
ATP Binding. A) Schematic representation of co-immunoprecipitation experiments 
using a FUS antibody as bait. B) Diagram portraying putative FUS binding partners 
filtering. C) Enrichment map created from GO Annotations and KEGG Pathways 
associated with putative FUS binding partners in yeast. Nodes highlighted in the yellow 
oval correspond to annotations related to ATP binding and nodes highlighted in the teal 




Figure 27. A large number of proteins co-immunoprecipitate with FUS. FUS 
antibody was used as a bait in a Co-IP experiment. The recovered proteins were 
separated on a SDS-PAGE gel and Silver stained for visualization (a). A number of 
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unique bands are present in the FUS Co-IP compared to the vector and bead alone 
controls, including a large band near the 34 kDa region. Verification that FUS was co-







Figure 28. Nop1 directly interacts with FUS. A) Recovered proteins from a Co-IP using 
a FUS antibody as bait were probed for Nop1 via Western Blotting. n = 3. B) Recovered 
proteins from a Reverse Co-IP using a Nop1 antibody as bait were probed for Nop1 via 
Western Blotting. n = 3 C) Recovered proteins from a reverse Co-IP using a Nop1 
antibody as bait were probed for FUS via Western Blotting. n = 3. D) FUS or control yeast 
were imaged by immunofluorescence with antibodies recognizing Nop1 (red), FUS 
(green) and counterstained with DAPI (blue). Examples of Nop1 and FUS colocalization 







Figure 29. Production of inserts for FLAG tag transformation and subsequent 
insertion were verified by 1% agarose gel electrophoresis followed by staining 






Figure 30. Levels of histone modifying enzymes do not change in the context of 
FUS proteinopathy. The levels of Ipl1 (A), Gcn5 (B) and Rtt109 (c) were measured in 
control and FUS yeast by Western blotting and probing against FLAG. a-Tubulin was 
used as a loading control. Histograms compiling multiple biological replicates display 
the mean fold change in FUS expression or aggregation based on densitometric 




Figure 31. Gcn5-FLAG does not mislocalize from the nucleus. FUS and control 
yeast containing Gcn5-Flag were imaged with immunofluorescence with antibodies 
recognizing Flag (red) and FUS (green) and counter stained with DAPI (blue, A). The 
percent of Flag in the nucleus was calculated and represented as a histogram (B). 
Colocalization between Flag and FUS in FUS yeast was calculated using the JACoP 




Figure 32. Rtt019-Flag is mislocalized from the nucleus. FUS and control yeast 
containing Rtt109-Flag were imaged with immunofluorescence with antibodies 
recognizing Flag (red) and FUS (green) and counter stained with DAPI (blue, A). The 
percent of Flag in the nucleus was calculated and represented as a histogram (B). 
Colocalization between Flag and FUS in FUS yeast was calculated using the JACoP 
plugin and correlation coefficients were averaged and represented as histogram (C). n = 
15, *** = p < 0.001.  
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Figure 33. Ipl1-FLAG mislocalizes from the nucleus and colocalizes with FUS. 
FUS and control yeast containing Ipl1-Flag were imaged with immunofluorescence with 
antibodies recognizing FLAG (red) and FUS (green) and counter stained with DAPI 
(blue, A). The percent of Flag in the nucleus was calculated and represented as a 
histogram (B). Examples of Ipl1-FLAG and FUS colocalization are shown with yellow 
arrows. Colocalization between FLAG and FUS in FUS yeast was calculated using the 
JACoP plugin and correlation coefficients were averaged and represented as histogram 
(C). n = 15, *** = p < 0.001.  
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Figure 34. FUS and Nop1 directly interact in Ipl1-FLAG yeast. The recovered 
proteins from a FUS Co-IP in control and FUS yeast transformed with Ipl1-FLAG were 
analyzed by Western blot and probed for FUS (a), Nop1 (b,). Similarly, the recovered 
proteins from Nop1 reverse Co-IP in control and FUS yeast transformed with Ipl1-FLAG 





Figure 35. FUS and Nop1 directly interact in Gcn5-FLAG yeast. The recovered 
proteins from a FUS Co-IP in control and FUS yeast transformed with Gcn5-FLAG were 
analyzed by Western blot and probed for FUS (a), Nop1 (b,). Similarly, the recovered 
proteins from Nop1 reverse Co-IP in control and FUS yeast transformed with Gcn5-





Figure 36. FUS and Nop1 directly interact in Ipl1-FLAG yeast. The recovered 
proteins from a FUS Co-IP in control and FUS yeast transformed with Rtt109-FLAG 
were analyzed by Western blot and probed for FUS (a), Nop1 (b,). Similarly, the 
recovered proteins from Nop1 reverse Co-IP in control and FUS yeast transformed with 






Figure 37. FUS and Nop1 do not interact with Ipl1-FLAG, Gcn5-FLAG or Rtt109-
FLAG. The recovered proteins from a FUS Co-IP and Nop1 reverse Co-IP in control 
and FUS yeast transformed with Ipl1-FLAG (a & b), Gcn5-FLAG (c & d) or Rtt109-FLAG 





Figure 38. Yeast overexpressing RRM display less growth suppression than yeast 
overexpressing wild type FUS. Spotting assays depict cell viability without and with galactose 





Figure 39. Levels of H3K14ac & H3K56ac are significantly reduced in FUS and RRM 
yeast. Representative immunoblots showing the levels of H3K14ac (A, n = 7) & H3K56ac (B, n 
= 7) for FUS and RRM yeast. Quantitation histograms compiling multiple biological replicates 
are presented alongside blots. All graphs display the mean fold change in modification levels for 
each group based on densitometric analysis of Western blots. Error bars indicate the +SD. ** = 




Figure 40. Levels of H3S10ph & H4R3me2asym are significantly reduced in FUS and 
RRM yeast. Representative immunoblots showing the levels of H3S10ph (A, n = 8) & 
H4R3me2asym (B, n = 6) for FUS and RRM yeast. Quantitation histograms compiling multiple 
biological replicates are presented alongside blots. All graphs display the mean fold change in 
modification levels for each group based on densitometric analysis of Western blots. Error bars 




Figure 41. RNA Levels Are Decreased in FUS and RRM yeast. Total RNA levels in 
yeast control cells and cells overexpressing FUS and RRM. Graph displays the mean 






Figure 42. Putative mechanism of how FUS is dysregulating histone PTMs and 




Chapter 5: Histone H3 Phosphorylation at Serine 10 is Dysregulated in 
Cellular Models of C9orf72 Expansion 
5.1 Rationale for studying for histone phosphorylation in the context of C9orf72 
ALS 
 A hexanucleotide repeat expansion (HRE, GGGGCC) between the first two 
exons in the C9orf72 gene is the most common cause of familial ALS,262, 263 and has 
been found in roughly 15% of sporadic cases.264 In general, the C9orf72 gene in healthy 
individuals contains up to 30 HRE; ALS patients carry hundreds to thousands of 
repeats.263, 265, 266 
 HREs in C9orf72 are thought to cause ALS through three pathogenic 
mechanisms: haploinsufficiency of C9orf72, toxic accumulation of RNA transcribed from 
the HREs and non-canonical repeat-associated non-ATG-dependent translation of the 
HRE RNA.264, 267, 268 This non-canonical translation can happen from either the sense or 
anti-sense strand, and produces the dipeptide repeat (DPRs) proteins poly-GP, poly-
GA, poly-GR, poly-PA and poly-PR. The arginine containing peptides are the most 
toxic.89, 269 It is now well established DRPs interfere with nuclear-cytoplasmic transport, 
contributing to HRE toxicity.89, 269-272 Although, to date, there is no research studying 
how DPRs may impact the epigenome. 
 Alterations to the histone PTM landscape have been observed in various ALS 
models.1, 18, 35, 73, 273-275 For instance, reduced levels of histone acetylation, methylation 
and phosphorylation have been observed in SH-SY5Y ALS proteinopathy models.274 
Recently, significantly reduced levels of global tri-methylation at lysine 9 on histone H3 
(H3K9me3) were discovered in a C9orf72 mouse model.275 Furthermore, significantly 
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altered levels of histone acetylation, methylation and phosphorylation in TDP-43 and 
FUS yeast models. 73 Here, we show that H3S10ph levels are considerably increased in 
yeast overexpressing the DPR PR50. Remarkably, we find a similar increase in 
H3S10ph levels in induced pluripotent stem cells (iPSCs) and fibroblasts derived from 
C9orf72 patients. We further show that Aurora B Kinase is enriched in the nucleus of a 
C9orf72 fibroblast line. Additionally, knockdown of Ipl1, the enzyme responsible for 
HS10 phosphorylation in yeast, reduces H3S10ph alterations and rescues the growth 
suppression phenotype. Our results suggest that H3S10ph alterations play a role in 
C9orf72 pathology, and highlight Aurora B kinase as a potential target for treatment of 
ALS. 
5.2 Overexpression of the dipeptide repeat protein PR50 is toxic in yeast 
 While inexpensive, time-efficient and easy to work with, yeast proteinopathy 
overexpression models recapitulate key proteinopathy features.89, 90, 159, 160, 164 We have 
previously exploited FUS and TDP-43 ALS yeast models to uncover associations with 
altered histone post-translational modification profiles.73 To characterize changes to the 
histone PTM landscape occurring in the context of C9orf72 ALS, we overexpressed the 
DPR PR50 in yeast. This model system has the advantage of isolating toxicity attributed 
to the DPR -as opposed to precursor RNA species- because it is codon optimized to not 
contain the hexanucleotide repeat expansions found in C9orf72.89 Moreover, yeast do 
not have a C9orf72 homolog, and thus there is no interference from a “loss of function” 
mechanism.89  
 We overexpressed the DPR PR50 in yeast in the presence of galactose and 
compared them to control yeast that were transformed with ccdB, a nonsense protein 
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acting as a vector control. As previously reported, PR50 overexpression is highly toxic 
(Figure 43a).89 The overexpression of FLAG-tagged PR50 was verified via Western 
blotting (Figure 43b).  
5.3 Histone phosphorylation and PR50 yeast 
5.3.1 H3S10ph levels are significantly increased in PR50 yeast 
To assess histone modification levels, yeast overexpressing PR50 and a vector 
control were subjected to Western blot analysis probing for histone post-translational 
modifications (PTM). PR50 expression was induced for 8 hours, as PR50 expression 
peaks at this time and precedes growth suppression (Figure 44). We surveyed a variety 
of histone modifications (Figure 45a). Remarkably, we observe an almost 2-fold 
increase in H3S10ph levels in PR50 yeast compared to control (Figure 45b).  
5.3.2. H3S10ph levels are tied to PR50 overexpression 
H3S10ph is linked to both transcriptional activation and silencing176. Ipl1, the 
yeast homologue of the mammalian Aurora B kinase, is responsible for installing this 
modification.276 Unfortunately, in the context of yeast cells, we were unable to determine 
whether the increase in H3S10ph arises from alterations in the levels of Ipl1 because 
antibodies for this protein are unavailable. To clarify if altered H3S10ph levels are tied to 
PR50 overexpression, we decreased PR50 levels by growing cells in varying ratios of 
sucrose and galactose. Sucrose gets slowly metabolized to glucose, and glucose in turn 
represses the galactose promoter. We first verified these conditions reduced PR50 
expression (Figure 46b).  Expectedly, decreased levels of PR50 lessened growth 
suppression in solid media, and as galactose concentration increased, so did growth 
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suppression (Figure 46a). Importantly, we find that lowering PR50 expression resulted in 
a decreased magnitude of change on H3S10ph (Figure 46c).  
5.4. H3S10ph levels are increased in C9orf72 human models 
5.4.1 H3S10ph levels in iPSCs 
Based on our findings in the yeast model, we wondered if H3S10ph levels are 
altered in human C9orf72 models. First, we compared H3S10ph levels in induced 
pluripotent stem cells (iPSC) derived from an ALS patient with expanded HREs 
compared to an age/sex matched control. Excitingly, H3S10ph levels were 
approximately 50% higher in histones isolated from the ALS patient (Figure 47a). To 
further validate that the rise in H3S10ph levels is due to the HRE in C9orf72 and not any 
other difference between the ALS sample and control, we exploited two C9orf72 ALS 
iPSC lines, C9n1 and C9n6, for which an isogenic control is available. Surprisingly, we 
not find a significant difference between the C9n1 ALS line and its isogenic control 
(Figure 47b). However, we did observe a significant increase in H3S10ph levels 
between the C9n6 ALS line and its isogenic control (Figure 47b). The reasons for the 
divergence in results from different cell lines is unclear, but it’s possible that there is less 
PR expression. The results from our yeast experiments suggest the PR drive the rise in 
H3S10ph levels, so it stands to reason the C9n1 line is not sufficiently expressing the 
DRP. 
5.4.2 H3S10ph levels in fibroblasts 
 We also measured the levels of H3S10ph in a fibroblast line derived from an 
C9orf72 ALS patient and an age and sex matched control. We observed significantly 
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higher levels in the C9orf72 line compared to the control (Figure 47c). Our results 
suggest that elevated H3S10ph levels are a hallmark of C9orf72 ALS.  
5.5 Aurora B Kinase is enriched in the nucleus of C9orf72 fibroblasts 
 Aurora B Kinase is responsible for phosphorylating H3S10. Hence, increased 
levels of H3S10ph could point to increased levels of Aurora B kinase in the nucleus. To 
determine whether the increase in H3S10ph arises from alterations in the levels of 
Aurora B kinase, we isolated the nuclear fraction from C9orf72 fibroblasts and age 
matched controls. We then measured the measured the levels of Aurora B Kinase in the 
nuclear fraction by Western blotting with a commercially-available Aurora B Kinase-
specific antibody. Intriguingly, we found that Aurora B Kinase levels are two-fold 
enriched in C9orf72 fibroblasts compared to its control (Figure 48). This result points to 
a potential role for Aurora B Kinase and histone phosphorylation in C9orf72 ALS.  
5.6 Reducing H3S10ph levels in PR50 yeast relieves toxicity 
5.6.1 Knockdown of Ipl1 rescues the growth suppression in PR50 yeast 
 Our results in fibroblast cell lines suggested that manipulation of the levels or the 
activity of Aurora B kinase could counter negative cellular outcomes. However, the lack 
of an obvious phenotype in human cellular models complicates these experiments. 
Opportunely, the overt cell death observed in PR50 yeast models plus the genetic tools 
available for S. cerevisiae enable expedient testing of this hypothesis. We investigated if 
lowering H3S10ph levels via reduction of kinase levels would reduce the toxicity 
observed in PR50 yeast. Ipl1, the enzyme responsible for phosphorylation H3S10 in 
yeast,176 is an essential gene and cannot be knocked out.277 To knock down Ipl1, we 
exploited the Decreased Abundance by mRNA Perturbation (DAmP) yeast library.278 
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DAmP yeast contain have compromised alleles of genes by inserting a kanamycin 
resistance gene in the 3’ untranslated region of gene, effectively reducing transcription 4 
to 10 fold.  
 We overexpressed PR50 in Ipl1 DAmP yeast and the DAmP parental strain, 
BY471. All lines grew normally on glucose, where the plasmid is not expressed (Figure 
49.a, left panel). Unsurprisingly, PR50 overexpression resulted in strong growth 
suppression in the parental strain compared to the vector control (Figure 49.a, right 
panel). Expression of PR50 was confirmed by western blotting (Figure 49.b). 
Remarkably, we observed growth protection in Ipl1 DAmP, with growth similar to the 
vector controls (Figure 49.a, right panel).  
5.6.2 Knockdown of Ipl1 reduces H3S10ph levels in PR50 yeast 
Expectedly, the parental strain yeast overexpressing PR50 displayed significantly 
higher H3S10ph levels compared to controls (Figure 50.b). Excitingly, we observed that 
Ipl1 DAmP yeast overexpressing PR50 displayed H3S10ph levels similar to those of 
control (Figure 50.a). These results support that Ipl1 and H3S10ph are contributing to 
the growth suppression observed in PR50 yeast, and that lowering levels of this 
H3S10ph may be a potential treatment option for C9orf72 ALS.  
5.7 Conclusions 
 HREs in the C9orf72 gene are the most common genetic cause of both familial 
and sporadic ALS.267 HREs in C9orf72 lead to the production of dipeptide repeat 
proteins (DPRs), including proline-arginine (PR).  Here, we exploited a yeast model to 
survey the histone PTM landscape in the context of PR50 overexpression. Remarkably, 
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we observed a large increase in the levels of H3S10ph in PR50 yeast compared to 
controls. The H3S10ph mark is an important PTM involved in gene regulation.176, 279 
Interestingly, we have observed H3S10ph dysregulation in a FUS overexpression yeast 
model of ALS, but there we observed a decrease in the levels of the PTM.73 
Remarkably, we have found FUS to secluded from the nucleus in the FUS 
overexpression model (unpublished), but our results in fibroblasts and Ipl1 DAmP yeast 
suggests the opposite in the context of C9orf72 HRE pathology. This strongly suggests 
that this PTM is associated with ALS pathology. 
 To expand on our yeast model results, we measured the levels of H3S10ph in 
isolated histones from various human in vitro ALS models. Importantly, H3S10ph levels 
rise in iPSCs and fibroblasts derived from C9orf72 ALS patients. This agreement 
between models strongly supports that increased H3S10ph levels contribute to DPR 
pathology. Of particular interest is the increase observed in the C9n6 iPSC cell line 
compared to an isogenic control. Perplexingly, we did not observe the same rise in 
H3S10ph levels in the C9n1 line compared to its isogenic control. Based on our results 
in the yeast model, we believe that the alteration to histone phosphorylation is due to 
PR. The PR DPR is derived from the antisense strand of the HRE in C9orf72.264, 280 
DPRs derived from the antisense strand are less abundant then DRPs derived from the 
sense strand.264, 281 It has also been recently shown that PR has a dose dependent 
effect on nuclear-cytoplasmic transport in regards to both concentration and length.269 It 
is possible that the C9n1 line had lower levels of PR, or even that the DPR was shorter 
in length, which may account for the lack of a rise in H3S10ph levels.  
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 We hypothesized that Ipl1/Aurora B Kinase was being trapped in the nucleus, 
leading to the increase of H3S10ph levels. We observed that Aurora B Kinase was 
enriched in the nuclear fraction of C9 fibroblasts, supporting our hypothesis. It is 
possible that Aurora B Kinase is being trapped in the nucleus either by lack of export or 
increased import. Hayes and colleagues showed that DPRs disrupted nuclear-
cytoplasmic transport through interaction with Importin b and cargo loading, not through 
clogging of the nuclear pore complex. They also observe that passive transport into the 
nucleus was increased in the presence of PR for proteins that can passively transport 
into the nucleus,269 such as Aurora B Kinase.282 Alternatively, PR has been found to 
localize to the nucleus, eject HP1a and alter constitution of heterochromatin.283 This 
change in heterochromatin was associated with increased levels of H34Kme3, leading 
to the toxic accumulation of expressed repetitive elements and double-stranded RNA. 
This change to chromatin structure may also contribute to the rise in H3S10ph, although 
HP1a is not conversed in yeast and cannot explain the rise in H3S10ph levels we 
observe in the PR50 overexpression model.  
 Altered gene expression has been reported in C9orf72 ALS patients.284, 285 As 
H3S10ph is an important regulator of transcription, it is possible that dysregulation of 
the PTM is leading to altered gene expression in PR associated C9orf2 pathology.  
Alternatively, H3S10ph is also a mark that begins mitosis in eukaryotes.286 Increasing 
levels of this mark may be forcing the cell into division, which may be particularly toxic 
to neurons in the G0 stage.287, 288 Interestingly, Aurora B Kinase has been found to be 
overexpressed in cancer cells, helping them to rapidly divide.289 The elevated levels of 
nuclear Aurora B Kinase and H3S10ph may be contributing to PR toxicity. Aurora B 
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inhibitors have been started to be used in the treatment of cancer,290 and potent 
inhibitors of Aurora B Kinase are currently available.291-294 Our results identify Aurora B 
as possible target for C9orf72 ALS treatment, and provide the added benefit of wide 
availability of safe drugs. Overall, our results support the role for an epigenetic 
mechanism contributing to PR and C9orf72 ALS pathology, adding to a growing body of 
research of epigenetics in ALS.1, 18, 73, 273, 274 
We reveal an increase in the phosphorylation of Histone H3 on Serine 10 
associated with C9orf72 expansions in yeast models, iPSCs and fibroblasts derived 
from patients. We hypothesize that alterations in H3S10ph contribute to the cellular 
demise observed in C9orf72 ALS. In particular, we postulate that the toxic effect of 
protein aggregation is related to its association to altered histone marks. Our model 
invokes protein aggregation leading to the retention and enhancement of Aurora B 
kinase’s activity in the nucleus. In turn, this causes disruptions in the levels of H3S10ph 
across the genome, resulting in heterochromatin disruption, aberrant regulation of 
specific genes and cell cycle re-entry.		
5.7 Experimental methods 
Materials All chemicals were purchased from Sigma-Aldrich (St. Louis, MO) unless 
otherwise specified. 
Yeast Strains, Media and Plasmids W303a (MATa, can1-100,his3-11, 
15,leu2,3,11,12,trp1-1,ura3-1,ade2-1)90 yeast were grown in synthetic media dropout 
medium (Clontech Laboratories, Mountain View, CA) supplemented with 2% glucose, 
raffinose or galactose. BY4741 (MATa, his3D1, leu2D0, met15D0, ura3D0) and Ipl1 
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DAmP yeast278 were grown in same media without ammonium sulfate (US Biologics, 
Memphis, TN, Cat No. Y2030). The PR50 plasmid (pAG303-Gal-PR50) was a gift from 
A. Gitler (Addgene plasmid no. 84905).89 A control ccdB plasmid, pAG303Gal-ccdB, 
was a gift from Susan Lindquist (Addgene plasmid no. 14133).90 W303 yeast were 
transformed using standard poly(ethylene glycol) and lithium acetate protocols.222 
BY4741 and Ipl1 DAmP yeast were transformed using a high efficiency protocol.295 
Serial Dilution Assays Yeast were grown to saturation overnight in raffinose-
supplemented dropout media at 30 °C. Overnight cultures were diluted 2-fold, then 
serially diluted 2-fold, then serially spotted onto synthetic dropout media supplemented 
with glucose, sucrose, galactose or a combination of sucrose and galactose. Plates 
were analyzed after growth for 3-4 days at 30 °C.  
PR50 Overexpression in Yeast PR50 overexpression in yeast was induced in 
galactose- or sucrose/galactose-containing medium at 30 °C. After induction, the PR50 
and ccdB control cultures were normalized to the same optical density and cell aliquots 
were harvested, snap frozen in liquid N2 and stored at -80 °C. All experiments were 
repeated a minimum of three times with three independently transformed strains. 
Yeast Lysis and Western Blotting Frozen yeast cell pellets were thawed and treated 
with 0.2 M NaOH for 10 minutes on ice, pelleted again, and subsequently resuspended 
in 100 µL of 1x SDS sample buffer and boiled for 10 minutes. Cell lysates were 
separated using SDS-PAGE (12, 18% or 4-20%, Bio-Rad, Hercules, CA, Cat No. 
4561094) and then transferred to a PVDF membrane (EMD Millipore). Membranes were 
blocked using LI-COR blocking buffer (LI-COR Biosciences, Lincoln, NE) for 1 hour at 
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RT. Membranes were incubated with primary antibodies at 4 °C overnight. Primary 
antibodies used were: mouse anti-Flag M2 (Cat. No. F3165, 1:1,000 dilution), mouse 
H4 total (Abcam, Cambridge, MA, Cat. No. ab10158), mouse anti-H3 total (Abcam, 
Cambridge, MA; Cat. No. ab24834, 1:2,000 dilution), rabbit anti-H3S10ph (Abcam, 
Cambridge, MA; cat. no. ab5176, 1:1,000 dilution). Blots were processed using goat 
anti-mouse and anti-rabbit secondary antibodies from LI-COR Biosciences (both at 
1:20,000 dilution) and imaged using an Odyssey Fc imaging system (LI-COR 
Biosciences). All immunoblotting experiments were independently repeated a minimum 
of three times. Densitometric analysis of Western blots was preformed using Image 
Studio (LI-COR Biosciences). The signals obtained for histone modifications were 
normalized to their respective total H3 signals (modification/total H3). These values 
were then compared with untreated control-sample values to obtain fold change values 
(sample/control), which were used for statistical analysis.  
Induced Pluripotent Stem Cell Culture C9 iPSC (subject ID NDS00239) and the age 
and sex matched control (subject ID NS00242) were obtained from the NINDS Human 
Cell and Data Repository. C9n1 (subject ID CS29iALS-C9xx), C9n6 (subject ID 
CS52iALS-C9xx) and their respective isogenic control lines (subject IDs CS29iALS-
C9n1.ISOxx & CS52iALS-C9n.ISOxx) were obtained the Cedars Sinai 
Biomanufacturing center. iPSCs were cultured on Matrigel Matrix (Corning, Corning, 
NY, Cat. No. 354277) coated 6-well plates with mTeSR1 (StemCell, Vancouver, 
Canada, Cat. No. 85850) supplemented with Y-27632 (StemCell, Vancouver, Canada, 
Cat. No. 72302) and 100 U/L Penicillin-Streptomycin (Gibco, Amarillo, TX, Cat. No. 15-
140-122) at 37 °C and 5% CO2. Cells were passaged with 1 U/mL Dispase (StemCell, 
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Vancouver, Canada, Cat. No. 07923) at ~75% confluency. During passaging, 10~20 
million cells were harvested by centrifugation at 400 g and 4 °C for 5 minutes, followed 
washing with 10 ml sterile DPBS (Gibco, Amarillo, TX, Cat. No. 14190144) two times. 
The resulting pellet was flash frozen in liquid N2 and stored at -80 °C. Each line was 
harvested at least three times. The morphology of the iPSCs were checked at each 
feeding to ensure purity. 
Fibroblast Cell Culture The C9 fibroblast line (Male, Age at Biopsy – 51) and its 
control (Male, Age at Biopsy – 39) were a gift from Jeffery Rothstein. Cells were 
cultured in T-75 flasks treated for cells culture (Greiner, Kremsmunster, Austria, Ca. No. 
07-000-225) in DMEM with Glutamax (Gibco, Amarillo, TX, 10-566-016) supplemented 
with 14% FB Essence (Avantor, Central Valley, PA, Cat. No. 10803-034) and 100 U/L 
Penicillin-Streptomycin (Gibco, Amarillo, TX, Cat. No. 15-140-122) at 37 °C and 5% 
CO2. Cells were passaged with 0.25% Trypsin (Gibco, Amarillo, TX, 15-050-065) at 
~75% confluency. During passaging, 5~15 million cells were harvested by centrifugation 
at 400 g and 4 °C for 5 minutes, followed washing with 10 ml sterile DPBS (Gibco, 
Amarillo, TX, Cat. No. 14190144) two times. The resulting pellet was flash frozen in 
liquid N2 and stored at -80 °C. Each line was harvested at least three times. The 
morphology of the fibroblasts was checked at each feeding to ensure purity. 
Histone Isolation Histone were isolated from C9 cultures by standard acid 
extraction.296, 297 Briefly, cell pellets were lysed in Nuclear Extraction Buffer (NIB, 15 mM 
Tris-HCl, 15 mM NaCl, 60 mM KCl, MgCl2, 1 mM CaCl2, 250 mM sucrose, 1 mM DTT, 
0.5 mM AEBSF, 5 nM Microcystin) + 0.2% NP-4 for 10 (iPSCs) or 15 (fibroblasts) 
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minutes on ice at a 10:1 vol/vol ratio, followed by three washes with NIB at 1,000 g for 5 
min at 4 °C at a 10:1 vol/vol ratio. The pellet was then resuspended in a 5:1 vol/vol ratio 
of 0.4 N H2SO4 and incubated with constant rotation for 4 hours at 4 °C. Cellular debris 
was removed by centrifugation at 3,400 g for 5 min at 4 °C, twice; each time the 
histone-containing supernatant was transferred to a fresh tube. Histones were then 
precipitated with 100% TCA O/N at 0°C. Histones were then pelleted by centrifugation 
at 3,400 g for 5 min at 4 °C, and washed with 0.1 HCl in acetone, followed by a final 
wash in pure acetone. The pellet was allowed to air dry completely and was then 
dissolved in nuclease free water. Protein concentration was measured with a Bradford 
Assay (Bio-Rad, Hercules, CA, Cat. No. 5000205). Samples were standardized to 0.07 
µg/µL. Histone purity was assessed by Coomassie (Bio-Rad, Hercules, CA, Cat. No. 
1610400) staining following SDS-PAGE on an 18% gel. H3S10ph levels on purified 
histones was then measured by Western blotting as described above. 
Nuclear Extraction The nuclear fraction was isolated from fibroblasts using a hypotonic 
solution.298 Briefly, cell pellets (~5 million cells) were resuspended in 500 µL of 
hypotonic buffer (20 nM Tris-HCl, 10 mM NaCl, 3 mM MgCl2) and incubated on ice for 
15 min, followed by addition of 25 µL of 10% NP-40 and vortexed on high for 4 °C. The 
sample was then centrifuged for 10 min at 3,000 rpm at 4 °C, the supernatant 
(containing the cytoplasmic fraction) was removed and saved, while the pellet 
(containing the nuclear fraction) was resuspended in Cell Extraction Buffer (10 mM Tris 
- pH 7.4, 2 mM Na3VO4, 100 mM NaCl, 1% Triton X-100, 1 mM EDTA, 10% glycerol, 1 
mM EGTA, 0.1% SDS, 1 mM NaF, 0.5% deoxycholate, 20 mM Na4P2O7) and incubated 
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on ice for 30 min, with vortexing at 10 min intervals. The nuclear fraction was then 
centrifuged for 30 min at 14,000 g at 4 °C for 30 min and supernatant (containing 
protein) was saved and protein concentration was measured with a Bradford Assay 
(Bio-Rad, Hercules, CA, Cat. No. 5000205) and standardized. Aurora B Kinase levels 
were measured by Western blotting as described above with an Aurora B Kinase 
specific antibody (Abcam, Cambridge, MA, ab2254, 1:1000 dilution) and H3 total 
(Abcam, Cambridge, MA; Cat. No. ab24834, 1:2,000 dilution). 
Statistical Analysis Statistical analysis of data was performed in RStudio 1.2.5001 using 
the built-in stats package (R-Project, Vienna, Austria). Significant differences between 
PR50 yeast (W303, BY4741 & Ipl1 DAmP), iPSCs and fibroblasts were determined using 
Welch’s t test with p = 0.05 as the cutoff. Significant differences between sucrose tuning 
treatment groups were determined using one-way ANOVA followed by Tukey’s test for 
pairwise comparison of the group means with p = 0.05 as the cutoff for significance. Error 
bars on the graphs represent standard deviation (SD) calculated from values obtained in 
the data analysis steps described above. All graphs were constructed with ggplot2 in 






Figure 43. Overexpression of PR50 is highly toxic in yeast. Yeast integrated with a 
gene encoded FUS or an empty vector were serially diluted 5-fold and spotted on 
glucose (off) or galactose (on) medium (A, n = 3). Representative Western blots 





Figure 44. PR50 expression peaks at eight hours. The optical density of liquid was 
culture was taken of 3 to 4 hours to create a growth curve (A, n = 2). Representative 





Figure 45. Overexpression of PR50 is associated with increased H3S10ph levels. A 
summary of the histone PTMs surveyed in this study (A). Significant changes are 
highlighted in red. Representative Western blot displaying H3S10ph levels and a 
histogram compiling multiple biological replicates are shown alongside (B, n = 5). Error 





Figure 46. The rise H3S10ph levels correlates with the expression of PR50. Spotting 
assays depict cell viability in glucose, sucrose, galactose and various ratios of sucrose 
and galactose (A, n = 3). Representative Western blots showing the expression of PR50 
(B, n = 3). Representative Western blot displaying H3S10ph levels and a histogram 
compiling multiple biological replicates are shown alongside (C, n = 4). Error bars 





Figure 47. H3S10ph levels are significantly raised in various C9 ALS in vitro 
models. Representative Western blots showing H3S10ph levels in isolated histones 
from age matched iPSCs (A, n = 5), isogenic iPSCs (B, n =5) and fibroblast (n = 3). 
Histograms compiling multiple biological replicates are shown alongside blots. Error 




Figure 48. Aurora B Kinase is significantly enriched in the nuclear fraction of C9 
Fibroblasts. Representative Western blot of Aurora B Kinase levels from the nuclear 
fraction of a C9 fibroblasts line and age matched control. Histogram compiling multiple 






Figure 49. Knockdown of Ipl1 rescues the growth suppression phenotype in PR50 
yeast. Yeast integrated with a gene encoded FUS or an empty vector in a parental and 
Ipl1 DAmP background were serially diluted 5-fold and spotted on glucose (off) or 
galactose (on) medium (A, n = 3). Representative Western blots showing the expression 






Figure 50. Ipl1 knockdown restore H3S10ph levels in PR50 yeast. Representative 
Western blot displaying H3S10ph levels in Ipl1 DAmP (A, n = 5) and parental strains (B 
n = 5). Histograms compiling multiple biological replicates are shown alongside. Error 
bars represent +SD. Representative. * = p < 0.05.	
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